This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Hariharan S, Johnson CP, Bresnahan BA, et al: Improved graft survival after renal transplantation in the United States, 1988 to 1996 [see comments]. N Engl J Med 342:605–612, 2000.
Sharing UNfO: Annual Report, the U.S. Scientific Registry of Transplant Recipients and the Organ Procurement and Transplantation Network 1999, pp. 7–8.
Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE: Infection in the renal transplant recipient. Am J Med 70:405–411, 1981.
Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM: Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 343:1078–1084, 2000.
Rubin R, Ikonen T, Gummert J, Morris R: The therapeutic prescription for the organ transplant recipient: The linkage of immunosuppression and antimicrobial strategies. Transplant Infect Dis 1:29–39, 1999.
Jamil B, Nicholls K, Becker GJ, Walker RG: Impact of acute rejection therapy on infections and malignancies in renal transplant recipients. Transplantation 68:1597–1603, 1999.
Miner JN, Brown M: Glucocorticoid action. In Austen K, Burakoff S, Rosen F, Strom T (eds): Therapeutic Immunology, ed. 2. Cambridge, Blackwell Science, 2001, pp. 103–116.
Fishman JA, Rubin RH: Infection in organ-transplant recipients [see comments]. N Engl J Med 338:1741–1751, 1998.
Tolkoff-Rubin N, Rubin R: Thepurine antagonists: Azathioprine and mycophenolate mofetil. In Austen K, Burakoff S, Rosen F, Strom T (eds): Therapeutic Immunology, ed. 2. Cambridge, Blackwell Science, 2001, pp. 51–64.
Opelz G, Dohler B: Critical threshold of azathioprine dosage for maintenance immunosuppression in kidney graft recipients. Collaborative Transplant Study. Transplantation 69:818–821, 2000.
Stolk JN, Boerbooms AM, De Abreu RA, van de Putte LB: Azathioprine treatment and thiopurine metabolism in rheumatic diseases. Introduction and first results of investigation. Adv Exp Med Biol 431:487–493, 1998.
Sebbag L, Boucher P, Davelu P, et al: Thiopurine S-methyl-transferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients. Transplantation 69:1524–1527, 2000.
Sollinger HW: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60:225–232, 1995.
Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group [see comments]. Lancet 345:1321–1325, 1995.
Kahan BD: Cyclosporine [see comments]. N Engl J Med 321: 1725–1738, 1989.
Schreiber SL: Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283–287, 1991.
Shapiro R, Jordan M, Scantlebury V, et al: FK 506 in clinical kidney transplantation. Transplant Proc 23:3065–3067, 1991.
Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE: Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation 59:390–395, 1995.
Gregory CR, Huie P, Billingham ME, Morris RE: Rapamycin inhibits arterial intimal thickening caused by both alloimmune and mechanical injury. Its effect on cellular, growth factor, and cytokine response in injured vessels. Transplantation 55:1409–1418, 1993.
Poon M, Marx SO, Gallo R, et al: Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 98:2277–2283, 1996.
Dominguez J, Mahalati K, Kiberd B, McAlister VC, MacDonald AS: Conversion to rapamycin immunosuppression in renal transplant recipients: Report of an initial experience [In Process Citation]. Transplantation 70:1244–1247, 2000.
Cosimi A: Antilymphocyte globulin-A final look. In Morris P, Tilney N (eds): Progress in Transplantation. Edinburgh, Churchill Livingstone, 1985, vol. 2, pp. 167–188.
Ortho Multicenter Transplant Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337–342, 1985.
Hibberd PL, Rubin RH: Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis 19(Suppl 1):S33–S40, 1994.
Soulillou JP, Cantarovich D, Le Mauff B, et al: Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts [see comments]. N Engl J Med 322:1175–1182, 1990.
Rubin RH, Tolkoff-Rubin NE: Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 37:619–624, 1993.
Rubin RH: Infectious disease complications of renal transplantation [clinical conference]. Kidney Int 44:221–236, 1993.
Sable CA, Hayden FG: Orthomyxoviral and paramyxoviral infections in transplant patients. Infect Dis Clin North Am 9:987–1003, 1995.
Rabella N, Rodriguez P, Labeaga R, et al: Conventional respiratory viruses recovered from immunocompromised patients: Clinical considerations. Clin Infect Dis 28:1043–1048, 1999.
Krinzman S, Basgoz N, Kradin R, et al: Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant 17:202–210, 1998.
McGrath D, Falagas ME, Freeman R, et al: Adenovirus infection in adult orthotopic liver transplant recipients: Incidence and clinical significance. J Infect Dis 177:459–462, 1998.
Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA: Adenovirus infection in the lung results in graft failure after lung transplantation. J Thome Cardiovasc Surg 116:617–623, 1998.
Simsir A, Greenebaum E, Nuovo G, Schulman LL: Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation 65:592–594, 1998.
Ghosh S, Champlin R, Couch R, et al: Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients [see comments]. Clin Infect Dis 29:528–532, 1999.
Vilchez RA, Fung JJ, Kusne S: Influenza A myocarditis developing in an adult liver transplant recipient despite vaccination: A case report and review of the literature. Transplantation 70:543–545, 2000.
Wittwer T, Pethig K, Heublein B, et al: Impact of chronic infection with chlamydia pneumoniae on incidence of cardiac allograft vasculopathy. Transplantation 69:1962–1964, 2000.
Hopkins CC, Weber DJ, Rubin RH: Invasive aspergillus infection: Possible non-ward common source within the hospital environment. J Hosp Infect 13:19–25, 1989.
Rubin RH: The compromised host as sentinel chicken [editorial]. N Engl J Med 317:1151–1153, 1987.
Allo MD, Miller J, Townsend T, Tan C: Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 317:1105–1108, 1987.
Kacmarek R, Kratohuil J, Dashevsky Y, et al: Performance of prototype portable HEPA-filtered positive pressure enclosures. Respir Care 37:1368, 1992.
Turgeon N, Hovingh G, Fishman J, et al: Safety and efficacy of granulocyte-colony stimulating factor in kidney and liver transplant recipients. Transplant Infect Dis 2:15–21, 2000.
Winston DJ, Foster PF, Somberg KA, et al: Randomized, placebocontrolled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 68:1298–1304, 1999.
Corales R, Chua J, Mawhortzer J, et al: Significant post-transplant hypogammaglobulinemia in six heart transplant recipients: An emerging clinical phenomenon. Transplant Infect Dis 2:133–139, 2000.
Darouiche RO: Anti-infective efficacy of silver-coated medical prostheses. Clin Infect Dis 29:1371–1377; quiz 1378, 1999.
Maki DG, Stolz SM, Wheeler S, Mermel LA: Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. A randomized, controlled trial [see comments]. Ann Intern Med 127:257–266, 1997.
Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 44:115–119, 1993.
Meier-Kriesche HU, Friedman G, Jacobs M, et al: Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols. Transplantation 68:1496–1502, 1999.
Meier-Kriesche HU, Ojo A, Magee JC, el al: African-American renal transplant recipients experience decreased risk of death due to infection: Possible implications for immunosuppressive strategies. Transplantation 70:375–379, 2000.
Freeman RB Jr, Tran CL, Mattoli J, et al: Tumor necrosis factor genetic polymorphisms correlate with infections after liver transplantation. NEMC TNF Study Group. New England Medical Center Tumor Necrosis Factor [published erratum appears in Transplantation 68(11):1823, 1999]. Transplantation 67:1005–1010, 1999.
Sahoo S, Kang S, Supran S, et al: Tumor necrosis factor genetic polymorphisms correlate with infections after renal transplantation. Transplantation 69:880–884, 2000.
Chang FY, Singh N, Gayowski T, et al: Thrombocytopenia in liver transplant recipients: Predictors, impact on fungal infections, and role of endogenous thrombopoietin. Transplantation 69:70–75, 2000.
Rubin R: Infectious disease problems. In Maddrey W (ed): Current Topics in Gastroenterology: Transplantation of the Liver. New York, Elsevier Science, 1988.
Johnson R, Rubin R: Respiratory disease in kidney and liver transplant recipients. In Shelhamer J, Pizzo P, Parrillo J, Masure H (eds): Respiratory Disease in the Immunosuppressed Host. Philadelphia, Lippincott, 1991, pp. 567–594.
Ettinger NA, Trulock EP: Pulmonary considerations of organ transplantation. Part I. Am Rev Respir Dis 143:1386–1405, 1991.
Argenziano M, Catanese KA, Moazami N, et al: The influence of infection on survival and successful transplantation in patients with left ventricular assist devices. J Heart Lung Transplant 16: 822–831, 1997.
LiPuma J: Burkholderia cepacia complex: A contraindication to lung transplantation in cystic fibrosis. Transplant Infect Dis 3:149–160, 2001.
Ramirez JC, Patterson GA, Winton TL, et al: Bilateral lung transplantation for cystic fibrosis. The Toronto Lung Transplant Group. J Thorac Cardiovasc Surg 103:287–293; discussion 294, 1992.
Trulock EP: Lung transplantation. Am J Respir Crit Care Med 155:789–818, 1997.
Walter S, Gudowius P, Bosshammer J, et al: Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis. Trorax 52: 318–321, 1997.
Kanj SS, Tapson V, Davis RD, Madden J, Browning I: Infections in patients with cystic fibrosis following lung transplantation [see comments]. Chest 112:924–930, 1997.
Nunley DR, Grgurich W, Lacono AT, et al: Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 113:1235–1243, 1998.
Venuta F, Boehler A, Rendina EA, et al: Complications in the native lung after single lung transplantation. Eur J Cardiothorac Surg 16:54–58, 1999.
Barker R, Mayes J, Schulak J: Wound abscesses following retroperitoneal pancreas transplantation. Clin Transplant 5:403–407, 1991.
Gupta D, Sakorafas GH, McGregor CG, Harmsen WS, Farnell MB: Management of biliary tract disease in heart and lung transplant patients [In Process Citation]. Surgery 128:641–649, 2000.
Papanicolaou GA, Meyers BR, Meyers J, et al: Nosocomial infections with vancomycin-resistant Enterococcus faecium in liver transplant recipients: Risk factors for acquisition and mortality. Clin Infect Dis 23:760–766, 1996.
Newell KA, Millis JM, Arnow PM, et al: Incidence and outcome of infection by vancomycin-resistant Enterococcus following orthotopic liver transplantation. Transplantation 65:439–442, 1998.
Singh N, Paterson DL, Chang FY, et al: Methicillin-resistant Staphylococcus aureus: The other emerging resistant grampositive coccus among liver transplant recipients. Clin Infect Dis 30:322–327, 2000.
Winston DJ, Emmanouilides C, Kroeber A, et al: Quinupristin/ dalfopristin therapy for infections due to vancomycin-resistant Enterococcus faecium. Clin Infect Dis 30:790–797, 2000.
McNeil SA, Clark NM, Chandrasekar PH, Kauffman CA: Successful treatment of vancomycin-resistant Enterococcus faecium bacteremia with linezolid after failure of treatment with synercid (quinupristin/dalfopristin). Clin Infect Dis 30:403–404, 2000.
Scowden EB, Schaffner W, Stone WJ: Overwhelming strongyloidiasis: An unappreciated opportunistic infection. Medicine 57: 527–544, 1978.
Morgan JS, Schaffner W, Stone WJ: Opportunistic strongyloidiasis in renal transplant recipients. Transplantation 42:518–524, 1986.
Purtilo DT, Meyers WM, Connor DH: Fatal strongyloidiasis in immunosuppressed patients. Am J Med 56:488–493, 1974.
DeVault GA Jr, King JW, Rohr MS, et al: Opportunistic infections with Strongyloides stercoralis in renal transplantation. Rev Infect Dis 12:653–671, 1990.
Scoggin CH, Call NB: Acute respiratory failure due to disseminated strongyloidiasis in a renal transplant recipient. Ann Intern Med 87:456–458, 1977.
Avagnina MA, Eisner B, Lotti RM, Re R: Strongyloides stercoralis in Papanicolaou-stained smears of ascitic fluid. Acta Cytol 24:36–39, 1980.
Venizelos PC, Lopata M, Bardawil WA, Sharp JT: Respiratory failure due to Strongyloides stercoralis in a patient with a renal transplant. Chest 78:104–106, 1980.
White JV, Garvey G, Hardy MA: Fatal strongyloidiasis after renal transplantation: A complication of immunosuppression. Am Surg 48:39–41, 1982.
Weller IV, Copland P, Gabriel R: Strongyloides stercoralis infection in renal transplant recipients. Br Med J (Clin Res Ed) 282:524, 1981.
Fowler CG, Lindsay I, Levin J, et al: Recurrent hyperinfestation with Strongyloides stercoralis in a renal allograft recipient. Br Med J (Clin Res Ed) 285:1394, 1982.
DeVault GA Jr, Brown STD, Montoya SF Jr, et al: Disseminated strongyloidiasis complicating acute renal allograft rejection. Prolonged thiabendazole administration and successful retransplantation. Transplantation 34:220–221, 1982.
Hirschmann JV, Plorde JJ, Ochi RF: Fever and pulmonary infiltrates in a patient with a renal transplant. West J Med 140:914–920, 1984.
Schad GA: Cyclosporine may eliminate the threat of overwhelming strongyloidiasis in immunosuppressed patients [letter]. J Infect Dis 153:178, 1986.
Schuraaker JD, Band JD, Lensmeyer GL, Craig WA: Thiabendazole treatment of severe strongyloidiasis in a hemodialyzed patient. Ann Intern Med 89:644–645, 1978.
Leapman SB, Rosenberg JB, Filo RS, Smith EJ: Strongyloides stercoralis in chronic renal failure: Safe therapy with thiabendazole. South Med J 73:1400–1402, 1980.
Jones C: Clinical studies in human strongyloidiasis. I. Semeiology. Gastroenterology 16:743–746, 1950.
Katkov W, Rubin R: Liver disease in the organ transplant recipient: Etiology, clinical impact, and clinical management. Transplant Rev 5:200–208, 1991.
Chan PC, Lok AS, Cheng IK, Chan MK: The impact of donor and recipient hepatitis B surface antigen status on liver disease and survival in renal transplant recipients. Transplantation 53:128–131, 1992.
Liang T, Baruch Y, Ben-Porath E, et al: HBV infection in patients with idiopathic liver disease. Hepatology 13:1044–1048, 1991.
Delmonico F: Cadaver donor screening for infectious agents in solid organ transplantation. Clin Infect Dis 31:781–786, 2000.
Madayag RM, Johnson LB, Bartlett ST, et al: Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease. Transplantation 64:1781–1786, 1997.
Dickson RC, Everhart JE, Lake JR, et al: Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology 113:1668–1674, 1997.
Uemoto S, Sugiyama K, Marusawa H, et al: Transmission of hepatitis B virus from hepatitis B core antibody-positive donors in living related liver transplants. Transplantation 65:494–499, 1998.
Van Thiel DH, De Maria N, Colantoni A, Friedlander L: Can hepatitis B core antibody positive livers be used safely for transplantation: Hepatitis B virus detection in the liver of individuals who are hepatitis B core antibody positive. Transplantation 68: 519–522, 1999.
Dodson SF, Issa S, Araya V, et al: Infectivity of hepatic allografts with antibodies to hepatitis B virus. Transplantation 64:1582–1584, 1997.
Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH: Th eclinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient [see comments]. Liver Transplant Surg 3:105–111, 1997.
Dodson SF, Bonham CA, Geller DA, et al: Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68:1058–1061, 1999.
Delmonico FL, Snydman DR: Organ donor screening for infec tious diseases: Review of practice and implications for transplantation. Transplantation 65:603–610, 1998.
Pereira BJ, Milford EL, Kirkman RL, Levey AS: Transmission of hepatitis C virus by organ transplantation [see comments]. N Engl J Med 325:454–460, 1991.
Pereira BJ, Milford EL, Kirkman RL, et al: Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs [see comments]. N Engl J Med 327:910–915, 1992.
Pereira BJ, Levey AS: Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 51:981–999, 1997.
Fishman JA, Rubin RH, Koziel MJ, Periera BJ: Hepatitis C virus and organ transplantation. Transplantation 62:147–154, 1996.
Miller J, Roth D, Schiff E: Hepatitis C and organ transplantation. N Engl J Med 328:312–317, 1998.
Widell A, Mansson S, Persson NH, et al: Hepatitis C superinfection in hepatitis C virus (HCV)-infected patients transplanted with an HCV-infected kidney. Transplantation 60:642–647, 1995.
Araya V, Rakela J, Wright T: Hepatitis C after orthotopic liver transplantation. Gastroenterotogy 112:575–582, 1997.
Kliem V, van den Hoff U, Brunkhorst R, et al: The long-term course of hepatitis C after kidney transplantation. Transplantation 62:1417–1421, 1996.
Bouthot BA, Murthy BV, Schmid CH, Levey AS, Pereira BJ: Long-term follow-up of hepatitis C virus infection among organ transplant recipients: Implications for policies on organ procurement. Transplantation 63:849–853, 1997.
Ong JP, Barnes DS, Younossi ZM, et al: Outcome of de novo hepatitis C virus infection in heart transplant recipients. Hepatology 30:1293–1298, 1999.
Everhart JE, Wei Y, Eng H, et al: Recurrent and new hepatitis C virus infection after liver transplantation [published erratum appears in Hepatology 30(4):1110, 1999]. Hepatology 29:1220–1226, 1999.
Vargas HE, Laskus T, Wang LF, et al: Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts [see comments]. Gastroenterology 117:149–153, 1999.
Feray C, Gigou M, Samuel D, et al: Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann Intern Med 128:810–816, 1998.
Pessoa MG, Terrault NA, Ferrell LD, et al: Hepatitis after liver transplantation: The role of the known and unknown viruses. Liver Transplant Surg 4:461–468, 1998.
Simonds RJ, Holmberg SD, Hurwitz RL, et al: Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor [see comments]. N Engl J Med 326:726–732, 1992.
Rubin RH, Tolkoff-Rubin NE: The problem of human immunodeficiency virus (HIV) infection and transplantation. Transplant Int 1:36–42, 1988.
Limaye AP, Connolly PA, Sagar M, et al: Transmission of Histoplasma capsulatum by organ transplantation. N Engl J Med 343: 1163–1166, 2000.
Ooi BS, Chen BT, Lim CH, Khoo OT, Chan DT: Survival of a patient transplanted with a kidney infected with Cryptococcus neoformans. Transplantation 11:428–429, 1971.
Gottesdiener KM: Transplanted infections: Donor-to-host transmission with the allograft. Ann Intern Med 110:1001–1016, 1989.
Rubin R, Fishman J: A consideration of potential donors with active infection—Is this a way to expand the donor pool? Transplant Int 11:333–335, 1998.
Johnston L, Chui L, Chang N, et al: Cross-Canada spread o methicillin-resistant Staphylococcus aureus via transplant organs. Clin Infect Dis 29:819–823, 1999.
Nelson PW, Delmonico FL, Tolkoff-Rubin NE, et al: Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation. Transplantation 37:313–314, 1984.
McCoy GC, Loening S, Braun WE, et al: The fate of cadaver renal allografts contaminated before transplantation. Transplantation 20:467–472, 1975.
Doig RL, Boyd PJ, Eykyn S: Staphylococcus aureus transmitted in transplanted kidneys. Lancet 2:243–245, 1975.
McLeish KR, McMurray SD, Smith EJ, Filo RS: The transmission of Candida albicans by cadaveric allografts. J Urol 118:513–516, 1977.
Caballero F, Lopez-Navidad A, Domingo P, et al: Successful transplantation of organs retrieved from a donor with enterococcal endocarditis. Transplant Int 11:387–389, 1998.
Anderson CB, Haid SD, Hruska KA, Etheredge EA: Significance of microbial contamination of stored cadaver kidneys. Arch Surg 113:269–271, 1978.
Hayry P, Renkonen OV: Frequency and fate of human renal allografts contaminated prior to transplantation. Surgery 85:404–407, 1979.
Majeski JA, Alexander JW, First MR, et al: Transplantation of microbially contaminated cadaver kidneys. Arch Surg 117:221–224, 1982.
Spees EK, Light JA, Oakes DD, Reinmuth B: Experiences with cadaver renal allograft contamination before transplantation. Br J Surg 69:482–485, 1982.
Owens ML, Wilson SE, Maxwell JG, et al: Major arterial hemorrhage after renal transplantation. Transplantation 27:285–287, 1979.
Fernando ON, Higgins AF, Moorhead JF: Letter: Secondary haemorrhage after renal transplantation. Lancet 2:368, 1976.
Weber TR, Freier DT, Turcotte JG: Transplantation of infected kidneys: Clinical and experimental results. Transplantation 27: 63–65, 1979.
Freeman RB, Giatras I, Falagas ME, et al: Outcome of transplantation of organs procured from bacteremic donors. Transplantation 68:1107–1111, 1999.
van der Vliet JA, Tidow G, Kootstra G, et al: Transplantation of contaminated organs. Br J Surg 67:596–598, 1980.
Slapak M: The immediate care of potential donors for cadaveric organ transplantation. Anaesthesia 33:700–709, 1978.
Burgos-Calderon R, Pankey GA, Figueroa JE: Infection in kidney transplantation. Surgery 70:334–340, 1971.
Moore TC, Hurne DM: The period and nature of hazard in clinical renal transplantation. 3. The hazard to transplant kidney survival. Ann Surg 170:25–29, 1969.
Schweizer RT, Kountz SL, Belzer FO: Wound complications in recipients of renal transplants. Ann Surg 177:58–62, 1973.
Diethelm AG: Surgical management of complications of steroid therapy. Ann Surg 185:251–263, 1977.
Muakkassa WF, Goldman MH, Mendez-Picon G, Lee HM: Wound infections in renal transplant patients. J Urol 130:17–19, 1983.
Lee HM, Madge GE, Mendez-Picon G, Chatterjee SN: Surgical complications in renal transplant recipients. Surg Clin North Am 58:285–304, 1978.
Kyriakides GK, Simmons RL, Najarian JS: Wound infections in renal transplant wounds: Pathogenetic and prognostic factors. Ann Surg 182:770–775, 1975.
Bruun JN: Post-operative wound infection. Predisposing factors and the effect of a reduction in the dissemination of staphylococci. Acta Med Scand Suppl 514:3–89, 1970.
Belzer FO, Salvatierra O Jr, Schweizer RT, Kountz SL: Prevention of wound infections by topical antibiotics in high risk patients. Am J Surg 126:180–185, 1973.
Tilney NL, Strom TB, Vineyard GC, Merrill JP: Factors contributing renal declining mortality rate in renal transplantation. N Engl J Med 299:1321–1325, 1978.
Novick AC: The value of intraoperative antibiotics in preventing renal transplant wound infections. J Urol 125:151–152, 1981.
Judson RT: Wound infection following renal transplantation. Aust NZ J Surg 54:223–224, 1984.
Fisher MC, Baluarte HJ, Long SS: Bacteremia due to Bacteroides fragilis after elective appendectomy in renal transplant recipients. J Infect Dis 143:635–638, 1981.
Morris PJ, Chan L, French ME, Ting A: Low dose oral prednisolone in renal transplantation. Lancet 1:525–527, 1982.
Howard RJ, Condie RM, Sutherland DE, Simmons RL, Najarian JS: The use of antilymphoblast globulin in the treatment of renal allograft rejection. Transplant Proc 13:473–474, 1981.
Palmer JM, Chatterjee SN: Urologic complications in renal transplantation. Surg Clin North Am 58:305–319, 1978.
Leary FJ, Woods JE, DeWeerd JH: Urologic problems in renal transplantation. Arch Surg 110:1124–1126, 1975.
Salvatierra O Jr, Olcott CT, Amend WJ Jr, Cochrum KC, Freduska NJ: Urological complications of renal transplantation can be prevented or controlled. J Urol 117:421–424, 1977.
Kohlberg WI, Tellis VA, Bhat DJ, Driscoll B, Veith FJ: Wound infections after transplant nephrectomy. Arch Surg 115:645–646, 1980.
Koehler PR, Kanemoto HH, Maxwell JG: Ultrasonic “B” scanning in the diagnosis of complications in renal transplant patients. Radiology 119:661–664, 1976.
Schweizer RT, Cho S, Koutz KS, Belzer FO: Lymphoceles following renal transplantation. Arch Surg 104:42–45, 1972.
Lorimer WS, Glassford DM, Sarles HE, Remmers Ar Jr, Fish JC: Lymphocele: A significant complication following renal transplantation. Lymphology 8:20–23, 1975.
Belzer F: Technical complications after renal transplantation. In Morris P (ed): Kidney Transplantation: Principles and Practice. New York, Academic Press, 1979, pp. 267–284.
Townsend TR, Rudolf LE, Westervelt FB Jr, Mandell GL, Wenzel RP: Prophylactic antibiotic therapy with cefamandole and tobramycin for patients undergoing renal transplantation. Infect Control 1:93–96, 1980.
Paya CV, Hermans PE: Bacterial infections after liver transplantation. Eur J Clin Microbiol Infect Dis 8:499–504, 1989.
Lebeau G, Yanaga K, Marsh JW, et al: Analysis of surgical complications after 397 hepatic transplantations. Surg Gynecol Obstet 170:317–322, 1990.
George DL, Arnow PM, Fox AS, et al: Bacterial infection as a complication of liver transplantation: Epidemiology and risk factors. Rev Infect Dis 13:387–396, 1991.
Barkholt L, Ericzon BG, Tollemar J, et al: Infections in human liver recipients: Different patterns early and late after transplantation. Transplant Int 6:77–84, 1993.
Korvick JA, Marsh JW, Starzl TE, Yu VL: Pseudomonas aeruginosa bacteremia in patients undergoing liver transplantation: An emerging problem. Surgery 109:62–68, 1991.
Jacobs F, Van de Stadt J, Gelin M, et al: Mycoplasma hominis infection of perihepatic hematomas in a liver transplant recipient [see comments]. Surgery 111:98–100, 1992.
Paya CV, Hermans PE, Washington JAD, et al: Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc 64:555–564, 1989.
Shaffer D, Jenkins RL, Karchmer AW, Monaco AP: Toxic shock syndrome complicating orthotopic liver transplantation—A case report. Transplantation 42:434–437, 1986.
Rosman C, Klompmaker IJ, Bonsel GJ, et al: The efficacy of selective bowel decontamination as infection prevention after liver transplantation. Transplant Proc 22:1554–1555, 1990.
van Zeijl JH, Kroes AC, Metselaar HJ, et al: Infections after auxiliary partial liver transplantation. Experiences in the first ten patients. Infection 18:146–151, 1990.
Wiesner RH, Hermans PE, Rakela J, et al: Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 45:570–574, 1988.
Wiesner RH: Selective bowel decontamination for infection prophylaxis in liver transplantation patients. Transplant Proc 23: 1927–1928, 1991.
Castaldo P, Stratta RJ, Wood RP, et al: Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 126:149–156, 1991.
Colonna JOd, Winston DJ, Brill JE, et al: Infectious complications in liver transplantation. Arch Surg 123:360–364, 1988.
Kusne S, Dummer JS, Singh N, et al: Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine 67:132–143, 1988.
Cuervas-Mons V, Barrios C, Garrido A, et al: Bacterial infections in liver transplant patients under selective decontamination with norfioxacin. Transplant Proc 21:3558, 1989.
Wajszczuk CP, Dummer JS, Ho M, et al: Fungal infections in liver transplant recipients. Transplantation 40:347–353, 1985.
Arnow PM, Furmaga K, Flaherty JP, George D: Microbiological efficacy and pharmacokinetics of prophylactic antibiotics in liver transplant patients. Antimscrob Agents Chetnother 36:2125–2130, 1992.
Arnow PM: Prevention of bacterial infection in the transplant recipient. The role of selective bowel decontamination. Infect Dis Clin North Am 9:849–862, 1995.
Paya CV: Fungal infections in solid-organ transplantation. Clin Infect Dis 16:677–688, 1993.
Hadley S, Karchmer AW: Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 9:1045–1074, 1995.
Tolkoff-Rubin NE, Conti DJ, Doran M, DelVecchio A, Rubin RH: Fluconazole in the treatment of invasive Candida) and cryptococcal infections in organ transplant recipients. Pharmacotherapy 10:159S–163S, 1990.
Goldmann DA, Hopkins CC, Karchmer AW, et al: Cephalothin prophylaxis in cardiac valve surgery. A prospective, double-blind comparison of two-day and six-day regimens. J Thorac Cardiovasc Surg 73:470–479, 1977.
Polk HC Jr, Lopez-Mayor JF: Postoperative wound infection: A prospective study of determinant factors and prevention. Surgery 66:97–103, 1969.
Platt R, Munoz A, Stella J, VanDevanter S, Koster JR Jr: Anti-biotic prophylaxis for cardiovascular surgery. Efficacy with coronary artery bypass. Ann Intern Med 101:770–774, 1984.
Remington JS, Gaines JD, Griepp RB, Shumway NE: Further experience with infection after cardiac transplantation. Transplant Proc 4:699–705, 1972.
Montgomery JR, Barrett FF, Williams TW Jr: Infectious complications in cardiac transplant patients. Transplant Proc 5:1239–1243, 1973.
Pearl SN, Weiner MA, Dibbell DG: Sternal infection after cardiac transplantation. Successful salvage utilizing a variety of techniques. J Thome Cardiovasc Surg 83:632–634, 1982.
Gorensek MJ, Stewart RW, Keys TF, et al: Decreased infections in cardiac transplant recipients on cyclosporine with reduced corticosteroid use. Cleve Clin J Med 56:690–695, 1989.
Petzold T, Feindt PR, Carl UM, Gams E: Hyperbaric oxygen therapy in deep sternal wound infection after heart transplantation. Chest 115:1455–1458, 1999.
Canver CC, Patel AK, Kosolcharoen P, Voytovich MC: Fungal purulent constrictive pericarditis in a heart transplant patient. Ann Thorac Surg 65:1792–1794, 1998.
Thomson D, Menkis A, Pflugfelder P, et al: Mycotic aortic aneurysm after heart-lung transplantation. Transplantation 47: 195–197, 1989.
Dowling RD, Baladi N, Zenati M, et al: Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg 49:118–122, 1990.
Anthuber M, Kernkes B, Kreuzer E, et al: Mediastinitis and mycotic aneurysm of the aorta after orthotopic heart transplantation. Tex Heart Inst J 18:186–193, 1991.
Palac RT, Strausbaugh LJ, Antonovic R, Floten HS: An unusual complication of cardiac transplantation-Infected aortic pseudoaneurysm. Ann Thorac Surg 51:479–481, 1991.
Slater AD, Ganzel BL, Keller M, Robin GRD, Gray LA Jr: Repair of infected pseudoaneurysm with aortic arch replacement after orthotopic heart transplantation. J Heart Transplant 9:230–235, 1990.
Phillips WS, Burton NA, Macmanus Q, Lefrak EA: Surgical complications in bridging to transplantation: The Thermo Cardiosystems LVAD [see comments], Ann Thorac Surg 53:482–485; discussion 485–486, 1992.
Edwards JE Jr, Bodey GP, Bowden RA, et al: International Conference for the Development of a Consensus on the Management and Prevention of Severe Candidal Infections [see comments]. Clin Infect Dis 25:43–59, 1997.
Busuttil RW, Goldstein LI, Danovitch GM, Ament ME, Memsic LD: Liver transplantation today [clinical conference], Ann Intern Med 104:377–389, 1986.
Starzl TE, Ishikawa M, Putnam CW, et al: Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc:6:129–139, 1974.
Schroter GP, Hoelscher M, Putnam CW, et al: Infections complicating orthotopic liver transplantation: A study emphasizing graft-related septicemia. Arch Surg 111:1337–1347, 1976.
Ho M, Wajszczuk C, Hardy A, et al: Infections in kidney, heart, and liver transplant recipients on cyclosporine. Transplant Proc 15:2768–2772, 1983.
Calne RY, Williams R: Liver transplantation. Curr Probl Surg 16:1–44, 1979.
Starzl TE, Iwatsuki S, Van Thiel DH, et al: Evolution of liver transplantation. Hepatology 2:614–636, 1982.
Starzl TE, Putnam CW, Hansbrough JF, Porter KA, Reid HA: Biliary complications after liver transplantation: With special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery 81:212–221, 1977.
Starzl T, Demetris A: Liver Transplantation: A 31 Year Perspective. Chicago, Year Book Medical, 1990.
Bubak ME, Porayko MK, Krom RA, Wiesner RH: Complications of liver biopsy in liver transplant patients: Increased sepsis associated with choledochojejunostomy. Hepatology 14:1063–1065, 1991.
Unilateral lung transplantation for pulmonary fibrosis. Toronto Lung Transplant Group. N Engl J Med 314:1140–1145, 1986.
Cooper JD: Current status of lung transplantation. Transplant Proc 23:2107–2114, 1991.
Dauber JH, Paradis IL, Dummer JS: Infectious complications in pulmonary allograft recipients. Clin Chest Med 11:291–308, 1990.
Tolkoff-Rubin NE, Cosimi AB, Delmonico FL, et al: Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. Transplantation 41:593–597, 1986.
Kreis H, Legendre C, Chatenoud L: OKT3 in organ transplantation. Transplant Rev 5:181–199, 1991.
Chatenoud L, Ferran C, Legendre C, et al: In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 49:697–702, 1990.
Basgoz N, Preiksaitis JK: Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 9:901–923, 1995.
Walker RC, Marshall WF, Strickler JG, et al: Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 20:1346–1353, 1995.
Rubin RH: Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 12(Suppl 7):S754–S766, 1990.
Cheeseman SH, Rubin RH, Stewart JA, et al: Controlled clinical trial of prophylactic human-leukocyte interferon in renal transplantation. Effects on cytomegalovirus and herpes simplex virus infections. N Engl J Med 300:1345–1349, 1979.
Betts RF, Freeman RB, Douglas RG Jr, Talley TE, Rundell B: Transmission of cytomegalovirus infection with renal allograft. Kidney Int 8:385–392, 1975.
Ho M, Suwansirikul S, Dowling JN, Youngblood LA, Armstrong JA: The transplanted kidney as a source of cytomegalovirus infection. N Engl J Med 293:1109–1112, 1975.
Suwansirikul S, Rao N, Dowling JN, Ho M: Primary and secondary cytomegalovirus infection. Arch Intern Med 137:1026–1029, 1977.
Naraqi S, Jackson GG, Jonasson O, Yamashiroya HM: Prospective study of prevalence, incidence, and source of herpesvirus infections in patients with renal allografts. J Infect Dis 136:531–540, 1977.
Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 24:458–464, 1977.
Chou SW: Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 314:1418–1423, 1986.
Grundy JE, Super M, Lui S, Sweny P, Griffiths PD: The source of cytomegalovirus infection in seropositive renal allograft recipients is frequently the donor kidney. Transplant Proc 19:2126–2128 1987.
Grundy JE, Lui SF, Super M, el al: Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 2:132–135, 1988.
Rubin R, Colvin R: The impact of CMV infections on renal transplantation. In Racusen L, Solez K, Burdick J (eds): Kidney Transplant Rejection. New York, Marcel Dekker, 1998, pp. 605–626.
Snydman DR, Werner BG, Dougherty NN, et al: Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo-controlled trial. The Boston Center for Liver Transplantation CMVIG Study Group. Ann Intern Med 119:984–991, 1993.
Rubin RH, Tolkoff-Rubin NE, Oliver D, et al: Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 40:243–249, 1985.
Tolkoff-Rubin NE, Rubin RH: Recent advances in the diagnosis and management of infection in the organ transplant recipient Semin Nephrol 20:148–163, 2000.
Chou SW, Norman DJ: The influence of donor factors other than serologic status on transmission of cytomegalovirus to transplant recipients. Transplantation 46:89–93, 1988.
Betts RF, Schmidt SG: Cytolytic IgM antibody to cytomegalovirus in primary cytomegalovirus infection in humans. J Infect Dis 143:821–826, 1981.
Betts RF: Cytomegalovirus infection in transplant patients. Prog Med Virol 28:44–64, 1982.
Huang ES, Alford CA, Reynolds DW, Stagno S, Pass RF: Molecular epidemiology of cytomegalovirus infections in women and their infants. N Engl J Med 303:958–962, 1980.
Drew WL, Sweet ES, Miner RC, Mocarski ES: Multiple infections by cytomegalovirus in patients with acquired immunodeficiency syndrome: Documentation by Southern blot hybridization. J Infect Dis 150:952–953, 1984.
Fryd DS, Peterson PK, Ferguson RM, Simmons RL, et al: Cytomegalovirus as a risk factor in renal transplantation. Transplantation 30:436–439, 1980.
Smiley ML, Wlodaver CG, Grossman RA, et al: The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation 40:157–161, 1985.
Chou SW: Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. J Infect Dis 160:11–15, 1989.
Ho M: Cytomegalovirus: Biology and Infection. New York, Plenum Medical, 1991.
Tolkoff-Rubin NA, Rubin RH, Keller EE, et al: Cytomegalovirus infection in dialysis patients and personnel. Ann Intern Med 89: 625–628, 1978.
Sagedal S, Nordal KP, Hartmann A, et al: A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients [In Process Citation]. Transplantation 70:1166–1174, 2000.
Rubin R, Kemmerly S, Conti D, et al: Prevention of primary cytomegalovirus disease in organ transplant recipients. Transplant Infect Dis 2:112–117, 2000.
Mach M, Stamminger T, Jahn G: Human cytomegalovirus: Recent aspects from molecular biology. J Gen Virol 70:3117–3146, 1989.
Mocarski ES, Kemble GW, Lyle JM, Greaves RF: A deletion mutant in the human cytomegalovirus gene encoding IEl(491aa) is replication defective due to a failure in autoregulation. Proc Natl Acad Sci USA 93:11321–11326, 1996.
Greaves RF, Mocarski ES: Defective growth correlates with reduced accumulation of a viral DNA replicationprotein after low-multiplicity infection by a human cytomegalovirus ie1 mutant. J Virol 72:366–379, 1998.
Reinke P, Prosch S, Kern F, Volk H: Mechanisms of human cytomegalovirus (HCMV) (re)activation and its impact on organ transplant patients. Transplant Infect Dis 1:157–164, 1999.
Fietze E, Prosch S, Reinke P, et al: Cytomegalovirus infection in transplant recipients. The role of tumor necrosis factor. Transplantation 58:675–680, 1994.
Stein J, Volk HD, Liebenthal C, Kruger DH, Prosch S: Tumour necrosis factor alpha stimulates the activity of the human cytomegalovirus major immediate early enhancer/promoter in immature monocytic cells. J Gen Viro l74:2333–2338, 1993.
Prosch S, Staak K, Stein J, et al: Stimulation of the human cytomegalovirus IE enhancer/promoter in HL-60 cells by TNF-alpha is mediated via induction of NFkB. Virology 208:107–116, 1995.
Docke WD, Prosch S, Fietze E, et al: Cytomegalovirus reactivation and tumour necrosis factor. Lancet 343:268–269, 1994.
Mutimer D, Mirza D, Shaw J, O’Donnell K, Elias E: Enhanced (cytomegalovirus) viral replicationassociated with septic bacterial complications in liver transplant recipients. Transplantation 63:1411–1415, 1997.
Mutimer DJ, Shaw J, O’Donnell K, Elias E: Enhanced (cytomegalovirus) viral replication after transplantation for fulminant hepatic failure [see comments]. Liver Transplant Surg 3:506–512, 1997.
Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G: High incidence of active cytomegalovirus infection among septic patients [see comments]. Clin Infect Dis 26:1076–1082, 1998.
Ho M: Cytomegalovirus infection in patients with bacterial sepsis [editorial comment]. Clin Infect Dis 26:1083–1084, 1998.
Brennan DC, Flavin K, Lowell JA, et al: A randomized, double-blinded comparison of thyroglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients [published erratum appears in Transplantation 67(10):1386, 1999]. Transplantation 67:1011–1018, 1999.
Paterson DL, Staplefeldt WH, Wagener MM, et al: Intraoperative hypothermia is an independent risk factor for early cytomegalovirus infection in liver transplant recipients. Transplantation 67:1151–1155, 1999.
Dowling JN, Saslow AR, Armstrong JA, Ho M: Cytomegalovirus infection in patients receiving immunosuppressive therapy for rheumatologic disorders. J Infect Dis 133:399–408, 1976.
Pass RF, Reynolds DW, Whelchel JD, Diethelm AG, Alford CA: Impaired lymphocyte transformation response to cytomegalovirus and phytohemagglutinin in recipients of renal transplants: Association with antithymocyte globulin. J Infect Dis 143:259–265, 1981.
Rubin RH, Cosimi AB, Hirsch MS, et al: Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation 31:143–145, 1981.
Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al: Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 53:68–72, 1992.
Gonwa TA, Capehart JE, Pilcher JW, Alivizatos PA: Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplantation 47:197–199, 1989.
Falagas ME, Snydman DR, Griffith J, et al: Clinical and epide miological predictors of recurrent cytomegalovirus disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 25:314–317, 1997.
Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G: Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis:247–253, 1999.
Sester M, Sester U, Gartner B, et al: Levels of virus-specific CD4 T-cells correlate with cytomegalovirus control and predict virus-induced disease following renal transplantation. In press.
Dechanet J, Merville P, Lim A, et al: Implication of gammadelta T cells in the human immune response to cytomegalovirus. J Clin Invest 103:1437–1449, 1999.
Zeevi A, Morel P, Spichty K, et al: Clinical significance of CMV-specific T helper responses in lung transplant recipients. Hum Immunol 59:768–775, 1998.
Asanuma H, Sharp M, Maecker HT, Maino VC, Arvin AM: Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis 181:859–866, 2000.
Gyulai Z, Endresz V, Burian K, et al: Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IEl-Exon4, gB, ppl50, and pp28 in healthy individuals: Reevaluation of prevalence of lEl-specific CTLs. J Infect Dis 181:1537–1546, 2000.
Wever PC, Spaeny LH, van der Vliet HJ, et al: Expression of granzyme B during primary cytomegalovirus infection after renal transplantation. J Infect Dis 179:693–696, 1999.
Hazzan M, Labalette M, Noel C, Lelievre G, Dessaint JP: Recall response to cytomegalovirus in allograft recipients: Mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28-cells within the CD8+ T lymphocyte compartment. Transplantation 63:693–698, 1997.
Cheeseman SH, Stewart JA, Winkle S, et al: Cytomegalovirus excretion 2–14 years after renal transplantation. Transplant Proc 11:71–74, 1979.
Fishman JA, Doran MT, Volpicelli SA, et al: Dosing of intravenous ganciclovir for the prophylaxis and treatment of cytomegalovirus infection in solid organ transplnt recipients. Transplantation 69:389–394, 2000.
Lazzarotto T, Varani S, Spezzacatena P, et al: Delayed acquisition of high-avidity anti-cytomegalovirus antibody is correlated with prolonged antigenemia in solid organ transplant recipients. J Infect Dis 178:1145–1149, 1998.
Nordoy I, Muller F, Nordal KP, et al: The role of the tumor necrosis factor system and interleukin-10 during cytomegalovirus infection in renal transplant recipients. J Infect Dis 181:51–57, 2000.
Millett R, Tomita T, Marshall HE, Cohen L, Hannah HD: Cytomegalovirus endomyocarditis in a transplanted heart. A case report with in situ hybridization. Arch Pathol Lab Med 115:511–515, 1991.
Calhoon JH, Nichols L, Davis R, et al: Single lung transplantation. Factors in postoperative cylomegalovirus infection. J Thorac Cardiovasc Surg 103:21–25; discussion 25–26, 1992.
Peterson PK, Balfour HH Jr, Fryd DS, Ferguson RM, Simmons RL: Fever in renal transplant recipients: Causes, prognostic significance and changing patterns at the University of Minnesota Hospital. Am J Med 71:345–351, 1981.
Simmons RL, Lopez C, Balfour H Jr, et al: Cytomegalovirus: Clinical virological correlations in renal transplant recipients. Ann Surg 180:623–634, 1974.
Simmons RL, Matas AJ, Rattazzi LC, et al: Clinical characteristics of the lethal cytomegalovirus infection following renal transplantation. Surgery 82:537–546, 1977.
Fine RN, Grushkin CM, Malekzadeh M, Wright HT Jr: Cytomegalovirus syndrome following renal transplantation. Arch Surg 105:564–570, 1972.
de Maar EF, Kas-Deelen AM, van der Mark TW, et al: Cytomegalovirus pneumonitis after kidney transplantation is not caused by plugging of cytomegalic endothelial cells only. Transplant Int 12:56–62, 1999.
Aafedt BC, Halvorsen RA Jr, Tylen U, Hertz M: Cytomegalovirus pneumonia: Computed tomography findings. Can Assoc Radiol J 41:276–280, 1990.
Jeffery JR, Guttmann RD, Becklake MR, Beaudoin JF, Morehouse DD: Recovery from severe cytomegalovirus pneumonia in a renal transplant patient. Am Rev Respir Dis 109:129–133, 1974.
Ravin CE, Smith GW, Ahern MJ, et al: Cytomegaloviral infection presenting as a solitary pulmonary nodule. Chest 71:220–222, 1977.
Hamed IA, Wenzl JE, Leonard JC, Altshuler GP, Pederson JA: Pulmonary cytomegalovirus infection: Detection by gallium 67 imaging in the transplant patient. Arch Intern Med 139:286–288, 1979.
Chinsky K, Goodenberger DM: Use of indium 111-labeled white blood cell scan in the diagnosis of cytomegalovirus pneumonia in a renal transplant recipient with a normal chest roentgenogram. Chest 99:761–763, 1991.
Friedman HM, Grossman RA, Plotkin SA, Perloff LJ, Barker CF: Relapse of pneumonia caused by cytomegalovirus in two recipients of renal transplants. J Infect Dis 139:465–473, 1979.
van Son WJ, van der Bij W, Tegzess AM, et al: Complement activation during an active cytomegalovirus infection after renal transplantation: Due to circulating immune complexes or alternative pathway activation? Clin Immunol Immunopathol 50:109–121, 1989.
van Son WJ, van der Bij W, The TH, et al: Evidence for pulmonary dysfunction in all patients with symptomatic and asymptomatic cytomegalovirus (CMV) infection after renal transplantation. Transplant Proc 21:2065–2068, 1989.
Cheung AK: Biocompatibility of hemodialysis membranes. J Am Soc Nephrol 1:150–161, 1990.
Stratta RJ, Shaefer MS, Markin RS, et al: Clinical patterns of cytomegalovirus disease after liver transplantation. Arch Surg 124:1443–1449; discussion 1449–1450, 1989.
Paya CV, Hermans PE, Wiesner RH, et al: Cytomegalovirus hepatitis in liver transplantation: Prospective analysis of 93 consecutive orthotopic liver transplantations. J Infect Dis 160:752–758, 1989.
Alessiani M, Kusne S, Fung JJ, et al: CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. Transplant Proc 23:3035–3037, 1991.
Backman L, Brattstrom C, Reinholt FP, Andersson J, Tyden G: Development of intrapancreatic abscess—A consequence of CMV pancreatitis? Transplant Int 4:116–121, 1991.
Klassen DK, Drachenberg CB, Papadimitriou JC, et al: CMV allograft pancreatitis: Diagnosis, treatment, and histological features. Transplantation 69:1968–1971, 2000.
Luby JP, Burnett W, Hull AR, et al: Relationship between cytomegalovirus and hepatic function abnormalities in the period after renal transplant. J Infect Dis 129:511–518, 1974.
Sutherland DE, Chan FY, Fourcar E, et al: The bleeding cecal ulcer in transplant patients. Surgery 86:386–398, 1979.
Minars N, Silverman JF, Escobar MR, Martinez AJ: Fatal cytomegalic inclusion disease. Associated skin manifestations in a renal transplant patient. Arch Dermatol 113:1569–1571, 1977.
Patel NP, Corry RJ: Cytomegalovirus as a cause of cecal ulcer with massive hemorrhage in a renal transplant recipient. Am Surg 46:260–262, 1980.
Franzin G, Muolo A, Griminelli T: Cytomegalovirus inclusions in the gastroduodenal mucosa of patients after renal transplantation. Gut 22:698–701, 1981.
van Son WJ, van der Jagt EJ, van der Woude FJ, et al: Pneumatosis intestinalis in patients after cadaveric kidney transplantation. Possible relationship with an active Cytomegalovirus infection. Transplantation 38:506–510, 1984.
Kaplan CS, Petersen EA, Icenogle TB, et al: Gastrointestinal Cytomegalovirus infection in heart and heart-lung transplant recipients. Arch Intern Med 149:2095–2100, 1989.
Escudero-Fabre A, Cummings O, Kirklin JK, Bourge RC, Aldrete JS: Cytomegaiovirus colitis presenting as hematochezia and requiring resection. Arch Surg 127:102–104, 1992.
Mayoral JL, Loeffler CM, Fasola CG, et al: Diagnosis and treatment of Cytomegalovirus disease in transplant patients based on gastrointestinal tract manifestations. Arch Surg 126:202–206, 1991.
Van Thiel DH, Gavaler JS, Schade RR, Chien MC, Starzl TE: Cytomegalovirus infection and gastric emptying. Transplantation 54:70–73, 1992.
Sakr M, Hassanein T, Gavaler J, et al: Cytomegalovirus infection of the upper gastrointestinal tract following liver transplantation-Incidence, location, and severity in cyclosporine-and FK506-treated patients. Transplantation 53:786–791, 1992.
Kaplan B, Meier-Kriesche HU, Jacobs MG, et al: Prevalence of Cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. Am J Kidney Dis 34:65–68, 1999.
Halme L, Hockerstedt K, Salmela K, Lautenschlager I: CMV infection detected in the upper gastrointestinal tract after liver transplantation. Transplant Int 11:S242–S244, 1998.
Tilsed JV, Morgan JD, Veitch PS, Donnelly PK: Reactivation of duodenal Cytomegalovirus infection mimicking a transplant lymphoma. Transplantation 54:945–946, 1992.
Battaglino MP, Rockey DC: Cytomegalovirus colitis presenting with the endoscopic appearance of pseudomembranous colitis. Gastrointest Endosc 50:697–700, 1999.
Crespo MG, Arnal FM, Gomez M, et al: Cytomegalovirus colitis mimicking a colonic neoplasm or ischemic colitis 4 years after heart transplantation. Transplantation 66:1562–1565, 1998.
Diaz-Gonzalez VM, Altemose GT, Ogorek C, Palazzo I, Pina IL: Cytomegalovirus infection presenting as an apple-core lesion of the colon. J Heart Lung Transplant 16:1171–1175, 1997.
Shapiro AM, Bain VG, Preiksaitis JK, et al: Ogilvie’s syndrome associated with acute cytomegaloviral infection after liver transplantation. Transplant Int 13:41–45, 2000.
Shutze WP, Kirklin JK, Cummings OW, Aldrete JS: Cytomegalovirus hemorrhoiditis in cardiac allograft recipients. Transplantation 51:918–920, 1991.
Moudgil A, Germain BM, Nast CC, et al: Ureteritis and cholecystitis: Two unusual manifestations of Cytomegalovirus disease in renal transplant recipients. Transplantation 64:1071–1073, 1997.
McLaughlin K, Cruickshank M, Hollomby D, Jevnikar A, Muirhead N: Idiopathic thrombocytopenia after cylomegalovirus infection in a renal transplant recipient. Am J Kidney Dis 33:e6, 1999.
Kashyap R, Shapiro R, Jordan M, Randhawa PS: The clinical significance of cytomegaloviral inclusions in the allograft kidney. Transplantation 67:98–103, 1999.
Peretti N, Said MH, Bouvier R, et al: Cytomegalovirus infection may cause ureteral necrosis. Transplantation 69:670–671, 2000.
Waiser J, Budde K, Rudolph B, Ortner MA, Neumayer HH: De novo hemolytic uremic syndrome postrenal transplant after Cytomegalovirus infection. Am J Kidney Dis 34:556–559, 1999.
Jeejeebhoy FM, Zaltzman JS: Thrombotic microangiopathy in association with Cytomegalovirus infection in a renal transplant patient: A new treatment strategy [see comments]. Transplantation 65:1645–1648, 1998.
Detwiler RK, Singh HK, Bolin P Jr, Jennette JC: Cytomegalovirus-induced necrotizing and crescentic glomerulonephritis in a renal transplant patient. Am J Kidney Dis 32:820–824, 1998.
Pouria S, State OI, Wong W, Hendry BM: CMV infection is associated with transplant renal artery stenosis.QJ Med 91:185–189, 1998.
Madalosso C, de Souza NF Jr, Ilstrup DM, Wiesner RH, Krom RA: Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation. Transplantation 66:294–297, 1998.
Sayage L, Gunby R, Gonwa T, et al: Cytomegalovirus endometritis after liver transplantation. Transplantation 49:815–817, 1990.
McCarthy JM, McLoughlin MG, Shackleton CR, et al: Cytomegalovirus epididymitis following renal transplantation. J Urol 146:417–419, 1991.
Dorfman LJ: Cytomegalovirus encephalitis in adults. Neurology 23:136–144, 1973.
Spitzer PG, Tarsy D, Eliopoulos GM: Acute transverse myelitis during disseminated Cytomegalovirus infection in a renal transplant recipient. Transplantation 44:151–153, 1987.
Aaberg TM, Cesarz TJ, Rytel MW: Correlation of virology and clinical course of Cytomegalovirus retinitis. Am J Ophthalmol 74:407–415, 1972.
De Venecia G, Zu Rhein GM, Pratt MV, Kisken W: Cytomegalic inclusion retinitis in an adult. Arch Ophthalmol 86:44–57, 1971.
Porter R, Crombie AL, Gardner PS, Uldall RP: Incidence of ocular complications in patients undergoing renal transplantation. Br Med J 3:133–136, 1972.
Wyhinny GJ. Apple DJ, Guastella FR, Vygantas CM: Adult cytomegalic inclusion retinitis. Am J Ophthalmol 76:773–781, 1973.
Astle JN, Ellis PP: Ocular complications in renal transplant patients. Ann Ophthalmol 6:1269–1274, 1974.
Nicholson D: Cytomegalovirus infection of the retina. In Pavan Langston D (ed): Ocular Viral Disease. Boston, Little, Brown, 1975, pp. 151–162.
Murray HW, Knox DL, Green WR, Susel RM: Cytomegalovirus retinitis in adults. A manifestation of disseminated viral infection. Am J Med 63:574–584, 1977.
Merritt JC, Callender CO: Adult cytomegalic inclusion retinitis. Ann Ophthalmol 10:1059–1063, 1978.
Carson S, Chatterjee SN: Cytomegalovirus retinitis: Two cases occurring after renal transplantation. Ann Ophthalmol 10:275–279, 1978.
Broughton WL, Cupples HP, Parver LM: Bilateral retinal detachment following cytomegalovirus retinitis. Arch Ophthalmol 96: 618–619, 1978.
Moeller MB, Gutman RA, Hamilton JD: Acquired cytomegalovirus retinitis. Four new cases and a review of the literature with implications for management. Am J Nephrol 2:251–255, 1982.
Fishburne BC, Mitrani AA, Davis JL: Cytomegalovirus retinitis after cardiac transplantation. Am J Ophthalmol 125:104–106, 1998.
Smit WM, Wagemans MA, Jansen CL, vd Horn GJ, Surachno JS: Acute retinal necrosis in a renal allograft recipient—An unusual manifestation of cytomegalovirus infection. Transplantation 55:219–221, 1993.
Blau EB, Gross JR: Congenital cytomegalovirus infection after recurrent infection in a mother with a renal transplant. Pediatr Nephrol 11:361–362, 1997.
Braun WE: Cytomegalovirus viremia and bacteremia in renalallograft recipients [letter]. N Engl J Med 299:1318–1319, 1978.
Rand KH, Pollard RB, Merigan TC: Increased pulmonary super-infections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 298:951–953, 1978.
Chatterjee SN, Fiala M, Weiner J, et al: Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients. JAMA 240:2446–2449, 1978.
George MJ, Snydman DR, Werner BG, et al: The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, Medlmmune, Inc. Gaithersburg, Maryland. Am J Med 103:106–113, 1997.
Husni RN, Gordon SM, Longworth DL, et al: Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 26:753–755, 1998.
Mackowiak PA, Goggans M, Torres W, et al: Relationship between cytomegalovirus and colonization of the oropharynx by gram-negative bacilli following renal transplantation. Epidemiol Infect 107:411–420, 1991.
Rifkind D: Pneumocystis carinii pneumonia in renal transplant recipients. Natl Cancer Inst Monogr 43:49–54, 1976.
Munda R, Alexander JW, First MR, Gartside PS, Fidler JP: Pulmonary infections in renal transplant recipients. Ann Surg 187:126–133, 1978.
Gantz NM, Myerowitz RL, Medeiros AA, et al: Listeriosis in immunosuppressed patients. A cluster of eight cases. Am J Med 58:637–643, 1975.
Schroter GP: Listeria monocytogenes and encephalitis [editorial]. Arch Intern Med 138:198–199, 1978.
Hooper DC, Pruitt AA, Rubin RH: Central nervous system infection in the chronically immunosuppressed. Medicine 61:166–188, 1982.
Rubin RH, Hooper DC: Central nervous system infection in the compromised host. Med Clin North Am 69:281–296, 1985.
Rytel MW, Balay J: Cytomegalovirus infection and immunity in renal allograft recipients: Assessment of the competence of humoral immunity. Infect Immun 13:1633–1637, 1976.
Baldwin WM, van Es A, Valentijn RM, et al: Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections. Clin Exp Immunol 50:515–524, 1982.
Baldwin WM, Claas FH, van Gemert GW, et al: IgM immune complexes, lymphocytotoxins, and rheumatoid factors in renal transplant recipients with CMV disease. Scand J Urol Nephrol Suppl 92:9–13, 1985.
Baldwin WM, Claas F, van Gemert G. et al: Studies on lymphocytotoxins and rheumatoid factors in renal transplant recipients with cytomegalovirus disease. Transplant Proc 17:616–617, 1985.
Linnemann CC Jr, Kauffman CA, First MR, Schiff GM, Phair JP: Cellular immune response to cytomegalovirus infection after renal transplantation. Infect Immun 22:176–180, 1978.
Glazer JP, Friedman HM, Grossman RA, et al: Live cytomegalovirus vaccination of renal transplant candidates. A preliminary trial. Ann Intern Med 91:676–683, 1979.
Reddehase MJ, Weiland F, Munch K, et al: Interstitial murine cytomegalovirus pneumonia after irradiation: Characterization of cells that limit viral replication during established infection of the lungs. J Virol 55:264–273, 1985.
Bukowski JF, Warner JF, Dennert G, Welsh RM: Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med 161:40–52, 1985.
Quinnan GV Jr, Kirmani N, Rook AH, et al: Cytotoxic T cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responsescorrelate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med 307:7–13, 1982.
Rook AH, Quinnan GV Jr, Frederick WJ, et al: Importance of cytotoxic lymphocytes during cytomegalovirus infection in renal transplant recipients. Am J Med 76:385–392, 1984.
Reusser P, Riddell SR, Meyers JD, Greenberg PD: Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 78:1373–1380, 1991.
Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infections in an adolescent without natural killer cells [see comments]. N Engl J Med 320:1731–1735, 1989.
Carney WP, Rubin RH, Hoffman RA, et al: Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol 126:2114–2116, 1981.
Doody DP, Wilson EJ, Medearis DN, Rubin RH: Changes in the phenotype of T-cell subset determinants following murine cytomegalovirus infection. Clin Immunol Immunopathol 40:466–475, 1986.
Schooley RT, Hirsch MS, Colvin RB, el al: Association of herpesvirus infections with T-lymphocyte-subset alterations, glomerulopathy, and opportunistic infections after renal transplantation. N Engl J Med 308:307–313, 1983.
van Es A, Baldwin WM, Oljans PJ, et al: Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation 37:65–69, 1984.
van den Berg AR van Son WJ, Janssen RA, et al: Recovery from cytomegalovirus infection is associated with activation of peripheral blood lymphocytes. J Infect Dis 166:1228–1235, 1992.
Craighead JE: Cytomegalovirus pulmonary disease. Pathobiol Annu 5:197–220, 1975.
Green GM: The J. Burns Amberson Lecture—In defense of the lung. Am Rev Respir Dis 102:691–703, 1970.
Rinaldo CR Jr, Black PH, Hirsch MS: Interaction of cytomegalovirus with leukocytes from patients with mononucleosis due to cytomegalovirus. J Infect Dis 136:667–678, 1977.
Levin MJ, Rinaldo CR Jr, Leary PL, Zaia JA, Hirsch MS: Immune response to herpesvirus antigens in adults with acute cytomegaloviral mononucleosis. J Infect Dis 140:851–857, 1979.
Carney WP, Hirsch MS: Mechanisms of immunosuppression in cytomegalovirus mononucleosis. II. Virus-monocyte interactions. J Infect Dis 144:47–54, 1981.
Rinaldo CR Jr, Carney WP, Richter BS, Black PH, Hirsch MS: Mechanisms of immunosuppression in cytomegaloviral mononucleosis. J Infect Dis 141:488–495, 1980.
Carney WP, Lacoviello V, Hirsch MS: Functional properties of T lymphocytes and their subsets in cytomegalovirus mononucleosis. J Immunol 130:390–393, 1983.
Schrier RD, Rice GP, Oldstone MB: Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus. J Infect Dis 153:1084–1091, 1986.
Rook AH, Masur H, Lane HC, et al: Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome. J Clin Invest 72:398–403, 1983.
Charpentier B, Espinosa O, Martin B, et al: T cell immunity against cytomegalovirus modifies self-major histocompatibility complex antigens in kidney transplant recipients. Transplant Proc 17:161–162, 1985.
Grundy JE: Virologic and pathogenetic aspects of cytomegalovirus infection. Rev Infect Dis 12(suppl. 7):S711–S719, 1990.
Grundy JE: Alterations of cellular proteins in human cytomegalovirus infection: Potential for disease pathogenesis. Transplant Proc 23:38–41, discussion 41–42, 1991.
Barnes PD, Grundy JE: Down-regulation of the class I HLA heterodimer and beta 2-microglobulin on the surface of cells infected with cytomegalovirus. J Gen Virol 73:2395–2403, 1992.
Joly E, Mucke L, Oldstone MB: Viral persistence in neurons explained by lack of major histocompatibility class I expression. Science 253:1283–1285, 1991.
Moskophidis D, Lechner F, Pircher H, Zinkernagel RM: Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells [published erratum appears in Nature 364(6434):262, 1993] [see comments]. Nature 362:758–761, 1993.
Dummer JS, Ho M, Rabin B, et al: The effect of cytomegalovirus and Epstein-Barr virus infection on T lymphocyte subsets in cardiac transplant patients on cyclosporine. Transplantation 38:433–435, 1984.
Hamilton JR, Overall JC, Glasgow LA: Synergistic effect on mortality in mice with murine cytomegalovirus and Pseudomonas aeruginosa, Staphylococcus aureus, or Candida albicans infections. Infect Immun 14:982–989, 1976.
Pomeroy C, Filice GA, Hitt JA, Jordan MC: Cytomegalovirus-induced reactivation of Toxoplasma gondii pneumonia in mice: Lung lymphocyte phenotypes and suppressor function. J Infect Dis 166:677–681, 1992.
Ward KN, Sheldon MJ, Gray JJ: Primary and recurrent cytomegalovirus infections have different effects on human herpesvirus-6 antibodies in immunosuppressed organ graft recipients: Absence of virus cross-reactivity and evidence for virus interaction. J Med Virol 34:258–267, 1991.
Simmons R, Weil R, Tallent M, et al: Do mild infections trigger the rejection of renal anografts? Transplant Proc 2:419–423, 1970.
Balfour HH Jr, Slade MS, Kalis JM, et al: Viral infections in renal transplant donors and their recipients: A prospective study. Surgery 81:487–492, 1977.
David DS, Millian SJ, Whitsell JC, et al: Viral syndromes and renal homograft rejection. Ann Surg 175:257–259, 1972.
Briggs JD, Timbury MC, Paton AM, Bell PR: Viral infection and renal transplant rejection. Br Med J 4:520–522, 1972.
Lopez C, Simmons RL, Mauer SM, et al: Association of renal allograft rejection with virus infections. Am J Med 56:280–289, 1974.
Belts RF, Freeman RB, Douglas RG Jr, Talley TE: Clinical manifestations of renal allograft derived primary cytomegalovirus infection. Am J Dis Child 131:759–763, 1977.
May AG, Betts RF, Freeman RB, Andrus CH: An analysis of cytomegalovirus infection and HLA antigen matching on the outcome of renal transplantation. Ann Surg 187:110–117, 1978.
von Willebrand E, Pettersson E, Ahonen J, Hayry P: CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 42:364–367, 1986.
Harmon J, Sibley R, Peterson P, et al: Cytomegalovirus viremia and renal allograft morphology: Are there distinct pathologic features? Lab Invest 46:35A, 1982.
Herrera GA, Alexander RW, Cooley CF, et al: Cytomegalovirus glomerulopathy: A controversial lesion. Kidney Int 29:725–733, 1986.
Boyce NW, Hayes K, Gee D, et al: Cytomegalovirus infection complicating renaltransplantation and its relationship to acute transplant glomerulopathy. Transplantation 45:706–709, 1988.
Shaver MJ, Bonsib SM, Abul-Ezz S, Barri YM: Renal allograft dysfunction associated with cytomegalovirus infection. Am J Kidney Dis 34:942–946, 1999.
Pouteil-Noble C, Ecochard R, Landrivon G, et al: Cytomegalovirus infection—An etiological factor for rejection? A prospective study in 242 renal transplant patients. Transplantation 55:851–857, 1993.
Cappel R, Hestermans O, Toussaint C, et al: Cytomegalovirus infection and graft survival in renal graft recipients. Arch Virol 56:149–156, 1978.
Hornef MW, Bein G, Fricke L, et al: Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 60:474–480, 1995.
Reinke P, Fietze E, Ode-Hakim S, et al: Late-acute renal allograft rejection and symptomless cytomegalovirus infection [see comments]. Lancet 344:1737–1738, 1994.
Reinke P, Fietze E, Docke WD, Kern F, et al: Late acute rejection in long-term renal allograft recipients. Diagnostic and predictive value of circulating activated T cells. Transplantation 58:35–41, 1994.
Ustinov JA, Loginov RJ, Mattila PM, et al: Cytomegalovirus infection of human kidney cells in vitro. Kidney Int 40:954–960, 1991.
Rubin RH: The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA 261:3607–3609, 1989.
Richardson WP, Colvin RB, Cheeseman SH, et al: Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 305:57–63, 1981.
Tuazon TV, Schneeberger EE, Bhan AK, et al: Mononuclear cells in acute allograft glomerulopathy. Am J Pathol 129:119–132, 1987.
O’Grady JG, Alexander GJ, Sutherland S, et al: Cytomegalovirus infection and donor/recipient HLA antigens: Interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 2:302–305, 1988.
Lautenschlager I, Hockerstedt K, Jalanko H, et al: Persistent cytomegalovirus in liver allografts with chronic rejection. Hepatology 25:190–194, 1997.
Evans PC, Coleman N, Wreghitt TG, Wight DG, Alexander GJ: Cytomegalovirus infection of bile duct epithelial cells, hepatic artery and portal venous endothelium in relation to chronic rejection of liver grafts. J Hepatol 31:913–920, 1999.
Martelius T, Krogerus L, Hockerstedt K, Bruggeman C, Lautenschlager I: Cytomegalovirus infection is associated with increased inflammation and severe bile duct damage in rat liver allografts. Hepatology 27:996–1002, 1998.
de Otero J, Gavalda J, Murio E, et al: Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation [see comments]. Clin Infect Dis 26:865–870, 1998.
Rubin RH: Cytomegalovirus disease and allograft loss after organ transplantation [editorial; comment]. Clin Infect Dis 26:871–873, 1998.
Falagas ME, Snydman DR, Griffith J, Ruthazer R, Werner BG: Effect of infection status on first-year mortality rates among orthotopic liver transplant recipients. The Boston Center for Liver Transplantation CMVIG Study Group [see comments]. Ann Intern Med 126:275–279, 1997.
Falagas ME, Paya C, Ruthazer R, et al: Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: A prospective derivation and validation cohort analysis. Transplantation 66:1020–1028, 1998.
Ontanon J, Muro M, Garcia-Alonso AM, et al: Effect of partial HLA class I match on acute rejection in viral pre-infected human liver allograft recipients. Transplantation 65:1047–1053, 1998.
Rosen HR, Corless CL, Rabkin J, Chou S: Association of cytomegalovirus genotype with graft rejection after liver transplantation. Transplantation 66:1627–1631, 1998.
Grattan MT, Moreno-Cabral CE, Starnes VA, et al: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261:3561–3566, 1989.
Loebe M, Schuler S, Spiegelsberger S, et al: [Cytomegalovirus infection and coronary sclerosis after heart transplantation]. Dtsch Med Wochenschr 115:1266–1269, 1990.
Loebe M, Schuler S, Zais O, et al: Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Transplant 9:707–711, 1990.
Weimar W, Balk AH, Metselaar HJ, Mochtar B, Rothbarth PH: On the relation between cytomegalovirus infection and rejection after heart transplantation. Transplantation 52:162–164, 1991.
Normann SJ, Salomon DR, Leelachaikul P, et al: Acute vascular rejection of the coronary arteries in human heart transplantation: Pathology and correlations with immunosuppression and cytomegalovirus infection. J Heart Lung Transplant 10:674–687, 1991.
McDonald K, Rector TS, Braulin EA, Kubo SH, Olivari MT: Associationof coronary artery disease in cardiac transplant recipients with cytomegalovirus infection [see comments]. Am J Cardiol 64:359–362, 1989.
Everett JP, Hershberger RE, Norman DJ, et al: Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 11:S133–S137, 1992.
Koskinen PK, Krogerus LA, Nieminen MS, et al: Quantitation of cytomegalovirus infection-associated histologic findings in endomyocardial biopsies of heart allografts. J Heart Lung Transplant 12:343–354, 1993.
Koskinen PK, Nieminen MS, Krogerus LA, et al: Cytomegalovirus infection accelerates cardiac allograft vasculopathy: Correlation between angiographic and endomyocardial biopsy findings in heart transplant patients. Transplant Int 6:341–347, 1993.
Koskinen P, Kallio E, Tikkanen J, et al: Cytomegalovirus infection and cardiacallograft vasculopathy. Transplant Infect Dis 1:115–126, 1999.
Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA: The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Am J Pathol 134:1151–1157, 1989.
Melnick JL, Adam E, DeBakey ME: Possible role of cytomegalovirus in atherogenesis. JAMA 263:2204–2207, 1990.
Orbaek Andersen H: Heart allograft vascular disease: An obliterative vascular disease in transplanted hearts. Atherosclerosis 142:243–263, 1999.
Melnick JL, Petrie BL, Dreesman GR, et al: Cytomegalovirus antigen within human arterial smooth muscle cells. Lancet 2: 644–647, 1983.
Tumilowicz JJ, Gawlik ME, Powell BB, Trentin JJ: Replication of cytomegalovirus in human arterial smooth muscle cells. J Virol 56:839–845, 1985.
Smiley ML, Mar EC, Huang ES: Cytomegalovirus infection and viral-induced transformation of human endothelial cells. J Med Virol 25:213–226, 1988.
Waldman WJ, Adams PW, Orosz CG, Sedmak DD: T lymphocyte activation by cytomegalovirus-infected, allogeneic cultured human endothelial cells. Transplantation 54:887–896, 1992.
Hosenpud JD, Chou SW, Wagner CR: Cytomegalovirus-induced regulation of major histocompatibility complex class 1 antigen expression in human aortic smooth muscle cells. Transplantation 52:896–903, 1991.
Grefte A, van der Giessen M, van Son W, The TH: Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection. J Infect Dis 167:270–277, 1993.
Grefte A, Blom N, Van der Giessen M, et al: Ultrastructural analysis of the circulating cytomegalic cells in patients with an active cytomegalovirus infection: Evidence for virus production and endothelial origin. J Infect Dis 168:1110–1118, 1993.
Srivastava R, Curtis M, Hendrickson S, Burns WH, Hosenpud JD: Strain specific effects of cytomegalovirus on endothelial cells: Implications for investigating the relationship between CMV and cardiac allograft vasculopathy. Transplantation 68: 1568–1573, 1999.
Milne DS, Gascoigne A, Wilkes J, et al: The immunohistopathology of obliterative bronchiolitis following lung transplantation. Transplantation 54:748–750, 1992.
Reinsmoen NL, Bolman RM, Savik K, Butters K, Hertz MI: Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection? Transplantation 55:1040–1044, 1993.
Nakhleh RE, Bolman RM, Henke CA, Hertz MI: Lung transplant pathology. A comparative study of pulmonary acute rejection and cytomegaloviral infection. Am J Surg Pathol 15:1197–1201, 1991.
Scott JP, Higenbottam TW, Sharpies L, et al: Risk factors for obliterative bronchiolitis in heart-lung transplant recipients [published erratum appears in Transplantation 52(2):388 1991]. Transplantation 51:813–817, 1991.
Keenan RJ, Lega ME, Dummer JS, et al: Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 51:433–438, 1991.
Smith MA, Sundaresan S, Mohanakumar T, et al: Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 116: 812–820, 1998.
Ross DJ, Jordan SC, Nathan SD, Kass RM, Koerner SK: Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials [see comments]. Chest 109:870–873, 1996.
Girgis RE, Tu I, Berry GJ, et al: Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant 15:1200–1208, 1996.
Humar A, Gillingham KJ, Payne WD, et al: Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients. Transplantation 68:1879–1883, 1999.
Evans PC, Soin A, Wreghitt TG, et al: An association between cytomegalovirus infection and chronic rejection after liver transplantation. Transplantation 69:30–35, 2000.
Kas-Deelen AM, de Maar EF, Harmsen MC, et al: Uninfected and cytomegalic endothelial cells in blood during cytomegalovirus infection: Effect of acute rejection. J Infect Dis 181:721–724, 2000.
Lemstrom KB, Bruning JH, Bruggeman CA, Lautenschlager IT, Hayry PJ: Cytomegalovirus infection enhances smooth muscle cell proliferation and intimal thickening of rat aortic allografts. J Clin Invest 92:549–558, 1993.
Koskinen P, Lemstrom K, Bruggeman C, Lautenschlager I, Hayry P: Acute cytomegalovirus infection induces a subendothelial inflammation (endothelialitis) in the allograft vascular wall. A possible linkage with enhanced allograft arteriosclerosis. Am J Pathol 144:41–50, 1994.
Lemstrom KB, Bruning JH, Bruggeman CA, et al: Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation 90:1969–1978, 1994.
Koskinen PK, Kallio EA, Bruggeman CA, Lemstrom KB: Cytomegalovirus infection enhances experimental obliterative bronchiolitis in rat tracheal allografts. Am J Respir Crit Care Med 155:2078–2088, 1997.
Reichenspurner H, Soni V, Nitschke M, et al: Enhancement of obliterative airway disease in rat tracheal allografts infected with recombinant rat cytomegalovirus. J Heart Lung Transplant 17: 439–451, 1998.
Lemstrom K, Sihvola R, Bruggeman C, Hayry P, Koskinen P: Cytomegalovirus infection-enhanced cardiac allograft vasculopathy is abolished by DHPG prophylaxis in the rat. Circulation 95:2614–2616, 1997.
Arbustini E, Morbini P, Grasso M, et al: Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung. Molecular, immunocytochemical, and histopathologic investigations. Transplantation 61:418–427, 1996.
Steinmuller C, Steinhoff G, Bauer D, et al: Analysis of leukocyte activation during acute rejection of pulmonary allografts in noninfected and cytomegalovirus-infected rats. J Leukoc Biol 61:40–49, 1997.
Arkonac B, Mauck KA, Chou S, Hosenpud JD: Low multiplicity cytomegalovirus infection of human aortic smooth muscle cells increases levels of major histocompatibility complex class I antigens and induces a pro-inflammatory cytokine milieu in the absence of cytopathology. J Heart Lung Transplant 16:1035–1045, 1997.
Dengler TJ, Raftery MJ, Werle M. Zimmerman R, Schonrich G: Cytomegalovirus infection of vascular cells induces expression of proinflammatory adhesion molecules by paracrine action of secreted interleukin-lbeta. Transplantation 69:1160–1168, 2000.
Knight DA, Waldman WJ, Sedmak DD: Cytomegalovirus-mediated modulation of adhesion molecule expression by human arterial and microvascular endothelial cells. Transplantation 68:1814–1818, 1999.
Iwamoto GK, Monick MM, Clark BD, et al: Modulation of interleukin 1 beta gene expression by the immediate early genes of human cytomegalovirus. J Clin Invest 85:1853–1857, 1990.
Iwamoto GK, Konicek SA: Cytomegalovirus immediate early genes upregulate interleukin-6 gene expression. J Invest Med 45:175–182, 1997.
Cebulla CM, Miller DM, Knight DA, et al: Cytomegalovirus induces sialyl Lewis(x) and Lewis(x) on human endothelial cells. Transplantation 69:1202–1209, 2000.
Lautenschlager I, Soots A, Krogerus L, et al: Effect of cytomegalovirus on an experimental model of chronic renal allograft rejection under triple-drug treatment in the rat. Transplantation 64:391–398, 1997.
Kloover JS, Soots AP, Krogerus LA, et al: Rat cytomegalovirus infection in kidney allograft recipients is associated with increased expression of intracellular adhesion molecule-1, vascular adhesion molecule-1, and their ligands leukocyte function antigen-1 and very late antigen-4 in the graft. Transplantation 69: 2641–2647, 2000.
van Dam JG, Li F, Yin M, et al: Effects of cytomegalovirus infection and prolonged cold ischemia on chronic rejection of rat renal allografts. Transplant Int 13:54–63, 2000.
Toyoda M, Galfayan K, Galera OA, et al: Cytomegalovirus infection induces anti-endothelial cell antibodies in cardiac and renal allograft recipients. Transplant Immunol 5:104–111, 1997.
Toyoda M, Petrosian A, Jordan SC: Immunological characterization of anti-endothelial cell antibodies induced by cytomegalovirus infection. Transplantation 68:1311–1318, 1999.
Span AH, Van Boven CP, Bruggeman CA: The effect of cytomegalovirus infection on the adherence of polymorphonuclear leucocytes to endothelial cells. Eur J Clin Invest 19:542–548, 1989.
Span AH, Endert J, van Boven CP, Bruggeman CA: Virus induced adherence of monocytes to endothelial cells. FEMS Microbiol Immunol 1:237–244, 1989.
Waldman WJ, Knight DA, Adams PW: Cytolytic activity against allogeneic human endothelia: Resistance of cytomegalovirus-infected cells and virally activated lysis of uninfected cells. Transplantation 66:67–77, 1998.
Craigen JL, Yong KL, Jordan NJ, et al: Human cytomegalovirus infection up-regulates interleukin-8 gene expression and stimulates neutrophil transendothelial migration. Immunology 92:138–145, 1997.
Grundy JE, Lawson KM, MacCormac LP, Fletcher JM, Yong KL: Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration. J Infect Dis 177:1465–1474, 1998.
Fujinami RS, Nelson JA, Walker L, Oldstone MB: Sequence homology and immunologic cross-reactivity of human cyto-megalovirus with HLA-DR beta chain: A means for graft rejection and immunosuppression. J Virol 62:100–105, 1988.
Beck S, Barrell BG: Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 331:269–272, 1988.
Grundy JE, Mackenzie JS, Stanley NF: Influence of H-2 and non-H-2 genes on resistance to murine cytomegalovirus infection. Infect Immun 32:277–286, 1981.
Allan JE, Shellam GR: Genetic control of murine cytomegalovirus infection: virus titres in resistant and susceptible strains of mice. Arch Virol 81:139–150, 1984.
Blancho G, Josien R, Douillard D, et al: The influence of HLA A-B-DR matching on cytomegalovirus disease after renal transplantation. Evidence that HLA-DR7-matched recipients are more susceptible to cytomegalovirus disease. Transplantation 54:871–874, 1992.
Manez R, White LT, Linden P, et al: The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation 55:1067–1071, 1993.
Humbert M, Delattre RM, Fattal S, et al: In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation 56:623–627, 1993.
Lebranchu Y, al Najjar A, Kapahi P, et al: The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients. Transplant Proc 27:960, 1995.
Grundy JE, Downes KL: Up-regulation of LFA-3 and ICAM-1 on the surface of fibroblasts infected with cytomegalovirus. Immunology 78:405–412, 1993.
Siegel DL, Fox I, Dafoe DC, et al: Discriminating rejection from CMV infection in renal allograft recipients using flow cytometry. Clin Immunol Immunopathol 51:157–171, 1989.
Grundy JE, Shearer GM: The effect of cytomegalovirus infection on the host response to foreign and hapten-modified self histocompatibility antigens. Transplantation 37:484–490, 1984.
Lowance D, Neumayer HH, Legendre CM, et al: Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group [see comments]. N Engl J Med 340:1462–1470, 1999.
Valantine HA, Gao SZ, Menon SG, et al: Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study. Circulation 100:61–66, 1999.
Valantine H: Role of CMV in transplant coronary artery disease and survival after heart transplantation. Transplant Infect Dis 1(Suppl):25–30, 1999.
Spector DH, Vacquier JP: Human cytomegalovirus (strain AD169) contains sequences related to the avian retrovirus oncogene v-myc. Proc Natl Acad Sci USA 80:3889–3893, 1983.
Gelmann EP, Clanton DJ, Jariwalla RJ, Rosenthal LJ: Characterization and location of myc homologous sequences in human cytomegalovirus DNA. Proc Natl Acad Sci USA 80:5107–5111, 1983.
Nelson JA, Fleckenstein B, Galloway DA, McDougall JK: Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169. J Virol 43:83–91, 1982.
Mueller N, Hinkula J, Wahren B: Elevated antibody titers against cytomegalovirus among patients with testicular cancer. Int J Cancer 41:399–403, 1988.
Ho M, Miller G, Alchison RW, et al: Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 152:876–886, 1985.
Chou S: Newer methods for diagnosis of cytomegalovirus infeclion. Rev Infect Dis 12(Suppl 7):S727–S736, 1990.
Chou SW: Neulralizing antibody responses to reinfecting strains of cylomegalovirus in transplant recipients. J Infect Dis 160:16–21, 1989.
Farrell HE, Shellam GR: Proleclion against murine cylomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 72:149–156, 1991.
Gretch DR, Kari B, Rasmussen L, Gehrz RC, Stinksi MF: Identificalion and characterization of three distinct families of glycoprolein complexes in the envelopes of human cytomegalovirus. J Virol 62:875–881, 1988.
Britt WJ, Vugler L, Stephens EB: Induction of complement-dependenl and-independent neutralizing antibodies by recombinanl-derived human cytomegalovirus gp55–16 (gB). J Virol 62:3309–3318, 1988.
Rasmussen L, Nelson M, Neff M, Merigan TC Jr: Characterizalion of two different human cylomegalovirus glycoproteins which are targets for virus neutralizing antibody. Virology 163: 308–318, 1988.
Rasmussen L, Malkin C, Spaete R, Pachl C, Merigan TC: Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis 164:835–842, 1991.
van Zanten J, van der Giessen M, van der Voort LH, et al: Cytomegalovirus-specific antibodies to an immediale early antigen and a late membrane antigen and their possible role in controlling secondary cylomegalovirus infection. Clin Exp Immunol 83:102–107, 1991.
Marshall GS, Rabalais GP, Stout GG, Waldeyer SL: Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity. J Infect Dis 165:381–384, 1992.
Chou S: Molecular epidemiology of envelope glycoprotein H of human cytomegalovirus. J Infect Dis 166:604–607, 1992.
Chou SW, Scoll KM: Rapid quantitation of cylomegalovirus and assay of neutralizing antibody by using monoclonal antibody to the major immediale-early viral protein. J Clin Microbiol 26: 504–507, 1988.
Gleaves CA, Smith TF, Shuster EA, Pearson GR: Comparison of standard tube and shell vial cell culture techniques for the deteclion of cytomegalovirus in clinical specimens. J Clin Microbiol 21:217–221, 1985.
Swenson PD, Kaplan MH: Rapid detection of cytomegalovirus in cell culture by indirect immunoperoxidase staining with monoclonal antibody to an early nuclear antigen. J Clin Microbiol 21: 669–673, 1985.
Paya CV, Wold AD, Smith TF: Detection of cylomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell cultures. J Clin Microbiol 25:755–757, 1987.
Marsano L, Perrillo RP, Flye MW, et al: Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients. J Infect Dis 161:454–461, 1990.
Dummer JS, White LT, Ho M, et al: Morbidily of cylomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis 152:1182–1191, 1985.
The TH, van der Ploeg M, van den Berg AP, et al: Direct detection of cytomegalovirus in peripheral blood leukocytes—A review of the antigenemia assay and polymerase chain reaction. Transplantation 54:193–198, 1992.
Gerna G, Revello MG, Percivalle E, et al: Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 28:2681–2688, 1990.
Miller H, Rossier E, Milk R, Thomas C: Prospective study of cytomegalovirus antigenemia in allograft recipients [see comments]. J Clin Microbiol 29:1054–1055, 1991.
Gerna G, Zipeto D, Parea M, et al: Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia. J Infect Dis 164:488–498, 1991.
van der Bij W, van Dijk RB, van Son WJ, et al: Antigen test for early diagnosis of active cytomegalovirus infection in heart transplant recipients. J Heart Transplant 7:106–109, 1988.
van den Berg AP, van der Bij W, van Son WJ, et al: Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation—A report of 130 consecutive patients. Transplantation 48:991–995, 1989.
van den Berg AP, Klompmaker IJ, Haagsma EB, et al: Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 164:265–270, 1991.
van den Berg AP, Tegzess AM, Scholten-Sampson A, et al: Monitoring antigenemia is useful in guiding treatment of severe cytomegalovirus disease after organ transplantation. Transplant Int 5:101–106, 1992.
Erice A, Holm MA, Gill PC, et al: Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes [see comments]. J Clin Microbiol 30:2822–2825, 1992.
Boland GJ, Ververs C, Hene RJ, et al: Early detection of primary cytomegalovirus infection after heart and kidney transplantation and the influence of hyperimmune globulin prophylaxis. Transplant Int 6:34–38, 1993.
Koskinen PK, Nieminen MS, Mattila SP, Hayry PJ, Lautenschlager IT: The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation 55:547–551, 1993.
Gaeta A, Nazzari C, Angeletti S, et al: Monitoring for cytomegalovirus infection in organ transplant recipients: Analysis of pp65 antigen, DNA and late mRNA in peripheral blood leukocytes. J Med Virol 53:189–195, 1997.
Saiki RK, Scharf S, Faloona F, et al: Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230:1350–1354, 1985.
van Dorp WT, Vlieger A, Jiwa NM, et al: The polymerase chain reaction, a sensitive and rapid technique for detecting cytomegalovirus infection after renal transplantation. Transplantation 54:661–664, 1992.
Fox JC, Griffiths PD, Emery VC: Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 73:2405–2408, 1992.
Bitsch A, Kirchner H, Dupke R, Bein G: Cytomegalovirus transcripts in peripheral blood leukocytes of actively infected transplant patients detected by reverse transcription-polymerase chain reaction. J Infect Dis 167:740–743, 1993.
Kotsimbos AT, Sinickas V, Glare EM, et al: Quantitative detection of human cytomegalovirus DNA in lung transplant recipients. Am J Respir Crit Care Med 156:1241–1246, 1997.
Abecassis MM, Koffron AJ, Kaplan B, et al: The role of PCR in the diagnosis and management of CMV in solid organ recipients: What is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? Transplantation 63:275–279, 1997.
Toyoda M, Carlos JB, Galera OA, et al: Correlation of cytomegalovirus DNA levels with response to antiviral therapy in cardiac and renal allograft recipients. Transplantation 63:957–963, 1997.
Evans PC, Soin A, Wreghitt TG, Alexander GJ: Qualitative and semiquantitative polymerase chain reaction testing for cytomegalovirus DNA in serum allows prediction of CMV related disease in liver transplant recipients. J Clin Pathol 51:914–921, 1998.
Pellegrin I, Garrigue I, Ekouevi D, et al: New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients. J Infect Dis 182:36–42, 2000.
Humar A, Gregson D, Caliendo AM, et al: Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 68:1305–1311, 1999.
Cope AV, Sweny P, Sabin C, et al: Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 52:200–205, 1997.
Cope AV, Sabin C, Burroughs A, et al: Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 176:1484–1490, 1997.
Mendez J, Espy M, Smith TF, et al: Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. Transplantation 65:1477–1481, 1998.
Hassan-Walker AF, Kidd IM, Sabin C, et al: Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients:Relationship with donor/ recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG). J Med Virol 58:182–187, 1999.
Roberts TC, Brennan DC, Buller RS, et al: Quantitative polymerase chain reaction to predict occurrence of symptomatic cytomegalovirus infection and assess response to ganciclovir therapy in renal transplant recipients. J Infect Dis 178:626–635, 1998.
Mas V, Alvarellos T, Albano S, et al: Utility of cytomegalovirus viral load in renal transplant patients in Argentina. Transplantation 67:1050–1055, 1999.
Tong CY, Cuevas LE, Williams H, Bakran A: Prediction and diagnosis of cytomegalovirus disease in renal transplant recipients using qualitative and quantitative polymerase chain reaction. Transplantation 69:985–991, 2000.
Barrett-Muir W, Breuer J, Millar C, et al: CMV viral load measurements in whole blood and plasma—Which is best following renal transplantation? Transplantation 70:116–119, 2000.
Emery VC, Sabin CA, Cope AV, et al: Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032–2036, 2000.
Sia IG, Wilson JA, Groettum CM, et al: Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation. J Infect Dis 181:717–720, 2000.
Emery V, Sabin C, Cope A, et al: Can the application of viral dynamics identify transplant patients destined to develop cytomegalovirus disease? Lancet 355:2032–2036, 2000.
Griffiths P, Cope A, Hassan-Walker A, Emery V: Diagnostic approach to cytomegalovirus infection in bone marrow and organ transplantation. Transplant Infect Dis 1:179–186, 1999.
De Witte T, Schattenberg A, Van Dijk BA, et al: Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 50:964–968, 1990.
Preiksaitis JK: Indications for the use of cytomegalovirus-seronegative blood products. Transfus Med Rev 5:1–17, 1991.
Sayers MH, Anderson KC, Goodnough LT, et al: Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 116:55–62, 1992.
Starr SE, Glazer JP, Friedman HM, Farquhar JD, Plotkin SA: Specific cellular and humoral immunity after immunization with live Towne strain cytomegalovirus vaccine. J Infect Dis 143: 585–589, 1981.
Plotkin SA, Smiley ML, Friedman HM, et al: Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1:528–530, 1984.
Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K: Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 12(Suppl7):S827–838, 1990.
Plotkin SA, Starr SE, Friedman HM, et al: Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial [see comments]. Ann Intern Med 114:525–531, 1991.
Spaete RR: A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23:90–96, 1991.
Rubin RH, Wilson EJ, Barrett LV, Medearis DN: The protective effects of hyperimmune anti-murine cytomegalovirus antiserum against lethal viral challenge: The case for passive-active immunization. Clin Immunol Immunopathol 39:151–158, 1986.
Roy DM, Grundy JE: Evaluation of neutralizing antibody titers against human cytomegalovirus in intravenous gamma globulin preparations [see comments]. Transplantation 54:1109–1110, 1992.
Snydman DR, Werner BG, Heinze-Lacey B, et al: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049–1054, 1987.
Snydman DR, Werner BG, Tilney NL, et al: A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and an open-label trial. Transplant Proc 20:24–30, 1988.
Snydman DR, Werner BG, Tilney NL, et al: Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: Comparison of the randomized and open-label trials. Transplant Proc 23: 1357–1360, 1991.
Tsevat J, Snydman DR, Pauker SG, et al: Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 52:259–265, 1991.
Metselaar HJ, Balk AH, Mochtar B, Rothbarth PH, Weimar W: Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin. Chest 97:396–399, 1990.
Metselaar HJ, Rothbarth PH, Brouwer RM, et al: Prevention of cytomegalovirus-related death by passive immunization. A double-blind placebo-controlled study in kidney transplant recipients treated for rejection. Transplantation 48:264–266, 1989.
Pakkala S, Salmela K, Lautenschlager I, Ahonen J, Hayry P: Anti-CMV hyperimmune globulin prophylaxis does not prevent CMV disease in CMV-negative renal transplant patients. Transplant Proc 24:283–284, 1992.
Falagas ME, Snydman DR, Ruthazer R, et al: Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 11:432–437, 1997.
Steinmuller DR, Novick AC, Streem SB, Graneto D, Swift C: Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 49:68–70, 1990.
Flynn JT, Kaiser BA, Long SS, et al: Intravenous immunoglobulin prophylaxis of cytomegalovirus infection in pediatric renal transplant recipients. Am J Nephrol 17:146–152, 1997.
Bock GH, Sullivan EK, Miller D, et al: Cytomegalovirus infections following renal transplantation—Effects on antiviral prophylaxis: A report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 11:665–671, 1997.
Balfour HH Jr, Chace BA, Stapleton JT, Simmons RL, Fryd DS: A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts [see comments]. N Engl J Med 320:1381–1387, 1989.
Balfour HH Jr: Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis Suppl 80:88–93, 1991.
Fletcher CV, Englund JA, Edelman CK, et al: Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients. Antimicrob Agents Chemother 35:938–943, 1991.
Vasquez EM, Sanchez J, Pollak R, et al: High-dose oral acyclovir prophylaxis for primary cytomegalovirus infection in seronegative renal allograft recipients. Transplantation 55:448–450, 1993.
Gavalda J, de Otero J, Murio E, et al: Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients. Transplant Int 10:462–465, 1997.
Rostaing L, Martinet O, Cisterne JM, et al: CMV prophylaxis in high-risk renal transplant patients (D+/R−) by acyclovir with or without hyperimmune (CMV) immunoglobulins: A prospective study. Am J Nephrol 17:489–494, 1997.
Badley AD, Seaberg EC, Porayko MK, et al: Prophylaxis of cytomegalovirus infection in liver transplantation: A randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 64:66–73, 1997.
Martin M, Manez R, Linden P, et al: A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 58:779–785, 1994.
Nicol DL, MacDonald AS, Belitsky P, et al: Reduction by combination prophylactic therapy with CMV hyperimmune globulin and acyclovir of the risk of primary CMV disease in renal transplant recipients. Transplantation 55:841–846, 1993.
Stratta RJ, Shaefer MS, Cushing KA, et al: Successful prophylaxis of cytomegalovirus disease after primary CMV exposure in liver transplant recipients. Transplantation 51:90–97, 1991.
Goral S, Ynares C, Dummer S, Helderman JH: Acyclovir prophylaxis for cytomegalovirus disease in high-risk renal transplant recipients: Is it effective? Kidney Int Suppl 57:S62–S65, 1996.
Flechner SM, Avery RK, Fisher R, et al: A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 66:1682–1688, 1998.
Avery RK: Prevention and treatment of cytomegalovirus infection and disease in heart transplant recipients. Curr Opin Cardiol 13:122–129, 1998.
Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM: Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: An economic evaluation. Transplantation 70:1463–1468, 2000.
Merigan TC, Renlund DG, Keay S, et al: A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med 326:1182–1186, 1992.
Wreghitt TG, Abel SJ, McNeil K, et al: Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transplant Int 12:254–260, 1999.
Seu P, Winston DJ, Holt CD, et al: Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. Transplantation 64:1614–1617, 1997.
Hertz MI, Jordan C, Savik SK, et al: Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 17:913–920, 1998.
Turgeon N, Fishman JA, Basgoz N, et al: Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving anti-lymphocyte antibody therapy. Transplantation 66:1780–1786, 1998.
Gane E, Saliba F, Valdecasas GJ, et al: Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group (corrected] [see comments] [published erratum appears in Lancet 351(9100): 454, 1997]. Lancet 350:1729–1733, 1997.
Ahsan N, Holman MJ, Yang HC: Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients. Clin Transplant 11:633–639, 1997.
Brennan DC, Garlock KA, Lippmann BA, et al: Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 8:118–125, 1997.
Pescovitz MD, Pruett TL, Gonwa T, et al: Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 66:1104–1107, 1998.
Pescovitz MD: Absence of teratogenicity of oral ganciclovir used during early pregnancy in a liver transplant recipient. Transplantation 67:758–759, 1999.
Bailey TC, Trulock EP, Ettinger NA, et al: Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 165:548–552, 1992.
Gerbase MW, Dubois D, Rothmeier C, et al: Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation [see comments]. Chest 116:1265–1272, 1999.
Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A: Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 67:315–320, 1999.
Gutierrez CA, Chaparro C, Krajden M, Winton T, Kesten S: Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 113:924–932, 1998.
Cen H, Breinig MC, Atchison RW, Ho M, McKnight JL: Epstein-Barr virus transmission via the donor organs in solid organ transplantation: Polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4. J Virol 65:976–980, 1991.
Schmidt GM, Horak DA, Niland JC, et al: A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; the City of Hope-Stanford-Syntex CMV Study Group [see comments]. N Engl J Med 324:1005–1011, 1991.
Goodrich JM, Mori M, Gleaves CA, et al: Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 325:1601–1607, 1991.
Egan JJ, Lomax J, Barber L, et al: Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients. Transplantation 65:747–752, 1998.
Kusne S, Grossi P, Irish W, et al: Cytomegalovirus PP65 anti-genemia monitoring as a guide for preemptive therapy: A cost effective strategy for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 68:1125–1131, 1999.
Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR: Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, controlled trial. Transplantation 70:717–722, 2000.
Kunzle N, Petignat C, Francioli P, et al: Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: Relationship between compliance with the guidelines and prevention of CMV morbidity. Transplant Infect Dis 2:118–126, 2000.
Pescovitz M: Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients. Transplant Infect Dis 1(Suppl l):31–34, 1999.
Jassal SV, Roscoe JM, Zaltzman JS, et al: Clinical practice guidelines: Prevention of cytomegalovirus disease after renal transplantation. J Am Soc Nephrol 9:1697–1708, 1998.
Dunn DL, Mayoral JL, Gillingham KJ, et al: Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 51:98–106, 1991.
Cooper DK, Novitzky D, Schlegel V, et al: Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant 10:656–662; discussion 662–663, 1991.
van den Berg AP, Tegzess AM, Scholten-Sampson A, et al: Quo vadis? The clinicaldilemma of simultaneous cytomegalovirus infection and steroid-resistant rejection. Transplantation 52: 1081–1083, 1991.
Burns KD, Johnson-Whittaker L, Couture RA, Eidus L, Garber G: Successful treatment of renal allograft rejection in the presence of cytomegalovirus disease. A report of two cases. Am J Nephrol 10:162–166, 1990.
de Koning J, van Dorp WT, van Es LA, van’ t Wout JW, van der Woude FJ: Ganciclovir effectively treats cytomegalovirus disease after solid-organ transplantation, even during rejection treatment. Nephrol Dial Transplant 7:350–356, 1992.
Duncan SR, Cook DJ: Survival of ganciclovir-treated heart trans-plant recipients with cytomegalovirus pneumonitis [see comments]. Transplantation 52:910–913, 1991.
Kruger RM, Shannon WD, Arens MQ, et al: The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation 68:1272–1279, 1999.
Bienvenu B, Thervet E, Bedrossian J, et al: Development of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient. Transplantation 69:182–184, 2000.
Alain S, Honderlick P, Grenet D, et al: Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient. Transplantation 63:1533–1536, 1997.
Sixbey JW, Nedrud JG, Raab-Traub N, Hanes RA, Pagano JS: Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 310:1225–1230, 1984.
Straus SE, Cohen JI, Tosato G, Meier J: NIH conference. Epstein-Barr virus infections: Biology, pathogenesis, and management. Ann Intern Med 118:45–58, 1993.
Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL: Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: Relationship to immunosuppressive therapy, serologic responses, and the risk of post-transplant lymphoproliferative disorder. J Infect Dis 166:986–994, 1992.
Miller G: The switch between latency and replication of Epstein-Barr virus. J Infect Dis 161:833–844, 1990.
Klein G: Viral latency and transformation: The strategy of Epstein-Barr virus. Cell 58:5–8, 1989.
Gregory CD, Dive C, Henderson S, et al: Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 349:612–614, 1991.
Pagano JS: Epstein-Barr virus: Culprit or consort? [editorial; comment] [see comments]. N Engl J Med 327:1750–1752, 1992.
Cohen JI: The biology of Epstein-Barr virus: Lessons learned from the virus and the host. Curr Opin Immunol 11:365–370, 1999.
Rowe DT: Epstein-Barr virus immortalization and latency. Front Biosci 4:D346–D371, 1999.
Tanner J, Alfieri C: The Epstein-Barr virus and post-transplant lymphoproliferative disease: Interplay of immunosuppression, EBV, and the immune system in disease pathogenesis. Transplant Infect Dis 3:60–69, 2001.
Sixbey JW, Shirley P, Chesney PJ, Buntin DM, Resnick L: Detection of a second widespread strain of Epstein-Barr virus. Lancet 2:761–765, 1989.
Sixbey JW, Shirley P, Sloas M, Raab-Traub N, Israele V: A transformation-incompetent, nuclear antigen 2-deleted Epstein-Barr virus associated with replicative infection. J Infect Dis 163:1008–1015, 1991.
Pisa P, Cannon MJ, Pisa EK, Cooper NR, Fox RI: Epstein-Barr virus induced lymphoproliferative tumors in severe combined immunodeficient mice are oligoclonal. Blood 79:173–179, 1992.
Birkeland SA, Bendtzen K, Moller B, Hamilton-Dutoit S, Andersen HK: Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 67: 876–881, 1999.
Vieira P, de Waal-Malefyt R, Dang MN, et al: Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: Homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 88:1172–1176, 1991.
Basgoz N, Hibberd P, Tolkoff-Rubin N, et al: Possible role of cytomegalovirus disease in the pathogenesis of post-transplant lymphoproliferative disorder. American Society of Transplant Physicians, 12th Annual Meeting, Houston, 1993.
Manez R, Breinig MC, Linden P, et al: Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 176:1462–1467, 1997.
Herbert D, Sullivan E: Malignancy and post-transplant lymphoproliferative disorder (PTLD) in pediatric renal transplant recipients: A report of the North American Pediatric Transplant Cooperative Study Group (NAPRTCS). Pediatr Transplant 2:57, 1998.
Paya CV, Fung JJ, Nalesnik MA, et al: Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 68:1517–1525, 1999.
Cockfield S: Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transplant Infect Dis 2001; 3 in press.
Hezode C, Duvoux C, Germanidis G, et al: Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation [see comments], Hepatology 30:775–778, 1999.
Cheeseman SH, Henle W, Rubin RH, et al: Epstein-Barr virus infection in renal transplant recipients. Effects of antithymocyte globulin and interferon. Ann Intern Med 93:39–42, 1980.
Spencer ES, Andersen HK: Clinically evident, non-terminal infections with herpesviruses and the wart virus in immunosuppressed renal allograft recipients. Br Med J 1:251–254, 1970.
Strauch B, Andrews LL, Siegel N, Miller G: Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1: 234–237, 1974.
Chang RS, Lewis JP, Reynolds RD, Sullivan MJ, Neuman J: Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferative disorders and by recipients of renal homografts. Ann Intern Med 88:34–40, 1978.
Grose C, Henle W, Horwitz MS: Primary Epstein-Barr virus infection in a renal transplant recipient. South Med J 70:1276–1278, 1977.
Marker SC, Ascher NL, Kalis JM, et al: Epstein-Barr virus antibody responses and clinical illness in renal transplant recipients. Surgery 85:433–440, 1979.
Salt A, Sutehall G, Sargaison M, et al: Viral and Toxoplasma gondii infections in children after liver transplantation. J Clin Pathol 43:63–67, 1990.
Randhawa PS, Markin RS, Starzl TE, Demetris AJ: Epstein-Barr virus-associated syndromes in immunosuppressed liver transplant recipients. Clinical profile and recognition on routine allograft biopsy. Am J Surg Pathol 14:538–547, 1990.
Stephaman E, Gruber S, Dunn D, et al: Posttransplant lymphoproliferative disorders. Transplant Rev 5:120–129, 1991.
Randhawa PS, Yousem SA: Epstein-Barr virus-associated lymphoproliferative disease in a heart-lung allograft. Demonstration of host origin by restriction fragment-length polymorphism analysis. Transplantation 49:126–130, 1990.
Jardine DL, Sizeland PC, Bailey RR, et al: Epstein-Barr virus infection acquired from a cadaveric renal transplant. Nephron 58: 359–361, 1991.
Canfield C, Hudnall S, Colonna J, et al: Fulminant Epstein-Barr virus associated post-transplant lymphoproliferative disorders following OKT3 therapy. Clin Transplant 6:1–9, 1992.
Denning DW, Weiss LM, Martinez K, Flechner SM: Transmission of Epstein-Barr virus by a transplanted kidney, with activation by OKT3 antibody. Transplantation 48:141–144, 1989.
Telenti A, Smith TF, Ludwig J, et al: Epstein-Barr virus and persistent graft dysfunction after liver transplantation. Hepatotogy 14:282–286, 1991.
Weissmann DJ, Ferry JA, Harris NL, et al: Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 103:748–755, 1995.
Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group [see comments]. Blood 84:1361–1392, 1994.
Harris NL, Ferry JA, Swerdlow SH: Posttransplant lymphoproliferative disorders: Summary of Society for Hematopathology Workshop. Semin Diagn Pathol 14:8–14, 1997.
Nalesnik M: The diverse pathology of post-transplant lymphoproliferative disorder: Importance of a standardized approach. Transplant Infect Dis 3:88–96, 2001.
Mutimer D, Kaur N, Tang H, et al: Quantitation of Epstein-Barr virus DNA in the blood of adult liver transplant recipients. Transplantation 69:954–959, 2000.
Vajro P, Lucariello S, Migliaro F, et al: Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease. J Infect Dis 181:2050–2054, 2000.
Green M, Reyes J, Webber S, et al: The role of viral load in the diagnosis, management, and possible prevention of Epstein-Barr virus-associated post-transplant lymphoproliferative disease following solid organ transplantation. Transplant Infect Dis 4:292–296, 1999.
Krieger NR, Martinez OM, Krams SM, et al: Significance of detecting Epstein-Barr-specific sequences in the peripheral blood of asymptomatic pediatric liver transplant recipients. Liver Transplant 6:62–66, 2000.
Preiksaitis J: Epstein-Barr virus infection and malignancy in solid organ transplant recipients: Strategies for prevention and treatment. Transplant Infect Dis 3:56–59, 2001.
Rowe D, Webber S, Shauer E, et al: Epstein-Barr virus load monitoring: Its role in the prevention and management of PTLD. Transplant Infect Dis. In press.
Malatack JF, Gartner JC Jr, Urbach AH, Zitelli BJ: Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concern [see comments]. J Pediatr 118:667–675, 1991.
Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al: Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients [see comments]. N Engl J Med 323:1723–1728, 1990.
Patton DF, Wilkowski CW, Hanson CA, et al: Epstein-Barr virus-determined clonality in posttransplant lymphoproliferative disease. Transplantation 49:1080–1084, 1990.
Nalesnik MA, Jaffe R, Starzl TE, et al: The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173–192, 1988.
Crawford DH, Sweny P, Edwards JM, Janossy G, Hoffbrand AV: Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet 1:10–12, 1981.
Bird AG, McLachlan SM, Britton S: Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 289:300–301, 1981.
Crawford DH, Edwards JM, Sweny P, Hoffbrand AV, Janossy G: Studies on long-term T-cell-mediated immunity to Epstein-Barr virus in immunosuppressed renal allograft recipients. Int J Cancer 28:705–709, 1981.
Yao QY, Rickinson AB, Gaston JS, Epstein MA: In vitro analysis of the Epstein-Barr virus: Host balance in long-term renal allograft recipients. Int J Cancer 35:43–49, 1985.
Hanto DW, Frizzera G, Purtilo DT, et al: Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 41: 4253–4261, 1981.
Kew CE 2nd, Lopez-Ben R, Smith JK, et al: Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation. Transplantation 69:809–814, 2000.
Heller T, Drachenberg CB, Orens JB, Fantry GT: Primary post-transplant lymphoproliferative disorder of the gallbladder in a lung transplant patient presenting with acute cholecystitis. Transplantation 69:668–670, 2000.
Oertel SH, Ruhnke MS, Anagnostopoulos I, et al: Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 67:765–767, 1999.
Green M, Reyes J, Webber S, Rowe D: The role of antiviral and immunoglobulin therapy in the prevention of Epstein-Barr virus infection and post-transplant lymphoproliferative disease following solid organ transplantation. Transplant Infect Dis 3:97–103, 2001 [review].
Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al: Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: Acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 306:913–918, 1982.
Pirsch JD, Stratta RJ, Sollinger HW, et al: Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases after solid organ transplantation. Am J Med 86:241–244, 1989.
Shapiro RS, Chauvenet A, McGuire W, et al: Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin [letter]. N Engl J Med 318:1334, 1988.
Rooney CM, Smith CA, Ng CY, et al: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 345:9–13, 1995.
Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB: Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: A new drug in therapy of patients with posttransplant lymphoproliferative disorder after solid organ transplantation? Transplantation 69:430–432, 2000.
Durandy A: Anti-B cell and anti-cytokine therapy for the treatment of PTLD: Past, present, and future. Transplant Infect Dis 3:104–107, 2001 [review].
Fischer A, Blanche S, Le Bidois J, et al: Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 324:1451–1456, 1991.
Korsager B, Spencer ES, Mordhorst CH, Andersen HK: Herpesvirus hominis infections in renal transplant recipients. Scand J Infect Dis 7:11–19, 1975.
Rubin RH, Tolkoff-Rubin NE: Viral infection in the renal transplant patient. Proc Eur Dial Transplant Assoc 19:513–526, 1983.
Ho M: Virus infections after transplantation in man. Brief review. Arch Virol 55:1–24, 1977.
Smyth RL, Higenbottam TW, Scott JP, et al: Herpes simplex virus infection in heart-lung transplant recipients. Transplantation 49:735–739, 1990.
Stone WJ, Scowden EB, Spannuth CL, Lowry SP, Alford RH: Atypical herpesvirus hominis type 2 infection in uremic patients receiving immunosuppressive therapy. Am J Med 63:511–516, 1977.
Burkhart CG: Persistent cutaneous herpes simplex infection. Int J Dermatol 20:552–554, 1981.
Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al: The renal transplant patient with fever and pulmonary infiltrates: Etiology, clinical manifestations, and management. Medicine 59:206–222, 1980.
Anuras S, Summers R: Fulminant herpes simplex hepatitis in an adult: Report of a case in renal transplant recipient. Gastroenterology 70:425–428, 1976.
Holdsworth SR, Atkins RC, Scott DF, Hayes K: Systemic herpes simplex infection with fulminant hepatitis post-transplantation. Aust N Z J Med 6:588–590, 1976.
Elliott WC, Houghton DC, Bryant RE, et al: Herpes simplex type 1 hepatitis in renal transplantation. Arch Intern Med 140:1656–1660, 1980.
Taylor RJ, Saul SH, Dowling JN, et al: Primary disseminated herpes simplex infection with fulminant hepatitis following renal transplantation. Arch Intern Med 141:1519–1521, 1981.
Naraqi S, Jackson GG, Jonasson OM: Viremia with herpes simplex type 1 in adults. Four nonfatal cases, one with features of chicken pox. Ann Intern Med 85:165–169, 1976.
Anora KK, Karalakulasingam R, Raff MJ, Martin DG: Cutaneous Herpesvirus hominis (type 2) infection after renal transplantation. JAMA 230:1174–1175, 1974.
Dummer JS, Armstrong J, Somers J, et al: Transmission of infection with herpes simplex virus by renal transplantation. J Infect Dis 155:202–206, 1987.
Dunn DL, Matas AJ, Fryd DS, Simmons RL, Najarian JS: Association of concurrent herpes simplex virus and cytomegalovirus with detrimental effects after renal transplantation. Arch Surg 119:812–817, 1984.
Griffin P, Colbert J, Williamson E, et al: Oral acyclovir prophylaxis of herpes infection in renal transplant recipients. Transplant Proc 17:84–85, 1985.
Pettersson E, Hovi T, Ahonen J, et al: Prophylactic oral acyclovir after renal transplantation. Transplantation 39:279–281, 1985.
Rifkind D: The activation of varicella-zoster virus infections by immunosuppressive therapy. J Lab Clin Med 68:463–474, 1966.
Luby JP, Ramirez-Ronda C, Rinner S, Hull A, Vergne-Marini P: A longitudinal study of varicella-zoster virus infections in renal transplant recipients. J Infect Dis 135:659–663, 1977.
Feldhoff CM, Balfour HH Jr, Simmons RL, Najarian JS, Mauer SM: Varicella in children with renal transplants. J Pediatr 98:25–31, 1981.
McGregor RS, Zitelli BJ, Urbach AH, Malatack JJ, Gartner JC Jr: Varicella in pediatric orthotopic liver transplant recipients. Pediatrics 83:256–261, 1989.
Lynfield R, Herrin JT, Rubin RH: Varicella in pediatric renal transplant recipients. Pediatrics 90:216–220, 1992.
Cohen JI, Brunell PA, Straus SE, Krause PR: Recent advances in varicella-zoster virus infection. Ann Intern Med 130:922–932, 1999.
Fall AJ, Aitchison JD, Krause A, et al: Donor organ transmission of varicella zoster due to cardiac transplantation. Transplantation 70:211–213, 2000.
Rothwell WS, Gloor JM, Morgenstern BZ, Milliner DS: Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. Transplantation 68:158–161, 1999.
Lawrence GL, Chee M, Craxton MA, et al: Human herpesvirus 6 is closely related to human cytomegalovirus. J Virol 64:287–299, 1990.
Sing N: Human herpesviruses-6,-7, and-8 in organ transplant recipients. Clin Microbial Infect 6:453–459, 2000.
Agut H: Puzzles concerning the pathogenicity of human herpesvirus 6 [editorial; comment]. N Engl J Med 329:203–204, 1993.
Flamand L, Gosselin J, Stefanescu I, Ablashi D, Menezes J: Immunosuppressive effect of human herpesvirus 6 on T-cell functions: Suppression of interleukin-2 synthesis and cell proliferation [published erratum appears in Blood 86(1):418, 1995]. Blood 85:1263–1271, 1995.
Knox KK, Carrigan DR: In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. J Infect Dis 165:925–929, 1992.
Carrigan DR, Knox KK: Human herpesvirus 6 (HHV-6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients [see comments]. Blood 84:3307–3310, 1994.
Oren I, Sobel JD: Human herpesvirus type 6: Review. Clin Infect Dis 14:741–746, 1992.
McCullers JA, Lakeman FD, Whitley RJ: Human herpesvirus 6 is associated with focal encephalitis. Clin Infect Dis 21:571–576, 1995.
Dockiell DH, Prada J, Jones MF, et al: Seroconversion to human herpesvirus 6 following liver transplantation is a marker of cytomegalovirus disease. J Infect Dis 176:1135–1140, 1997.
Ward KN, Gray JJ, Efstathiou S: Brief report: Primary human herpesvirus 6 infection in a patient following liver transplantation from a seropositive donor. J Med Virol 28:69–72, 1989.
Kikuta H, Itami N, Matsumoto S, Chikaraishi T, Togashi M: Frequent detection of human herpesvirus 6 DNA in peripheral blood mononuclear cells from kidney transplant patients [letter]. J Infect Dis 163:925, 1991.
Okuno T, Higashi K, Shiraki K, et al: Human herpesvirus 6 infection in renal transplantation. Transplantation 49:519–522, 1990.
Gudnason T, Dunn D, Brown N, et al: Human herpesvirus 6 infections in hospitalized renal transplant recipients. Clin Transplant 5:359–364, 1991.
Yoshikawa T, Suga S, Asano Y, et al: A prospective study of human herpesvirus-6 infection in renal transplantation. Transplantation 54:879–883, 1992.
Sutherland S, Christofinis G, O’Grady J, Williams R: A serological investigation of human herpesvirus 6 infections in liver transplant recipients and the detection of cross-reacting antibodies to cytomegalovirus. J Med Virol 33:172–176, 1991.
Chou SW, Scott KM: Rises in antibody to human herpesvirus 6 detected by enzyme immunoassay in transplant recipients with primary cytomegalovirus infection. J Clin Microbiol 28:851–854, 1990.
Singh N, Paterson DL: Encephalitis caused by human herpesvirus-6 in transplant recipients: Relevance of a novel neurotropic virus. Transplantation 69:2474–2479, 2000.
Dockrell DH, Smith TF, Paya CV: Human herpesvirus 6. Mayo Clin Proc 74:163–170, 1999.
Griffiths PD, Ait-Khaled M, Bearcroft CP, et al: Human herpesviruses 6 and 7 as potential pathogens after liver transplant: Prospective comparison with the effect of cytomegalovirus. J Med Virol 59:496–501, 1999.
Chan PK, Peiris JS, Yuen KY, et al: Human herpesvirus-6 and human herpesvirus-7 infections in bone marrow transplant recipients. J Med Virol 53:295–305, 1997.
Tong CY, Bakran A, Williams H, Cheung CY, Peiris JS: Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients. Transplantation 70:213–216, 2000.
Kidd IM, Clark DA, Sabin CA, et al: Prospective study of human beta herpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection. Transplantation 69:2400–2404, 2000.
Brennan DC, Storch GA, Singer GG, et al: The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir. J Infect Dis 181:1557–1561, 2000.
Mendez JC, Procop GW, Espy MJ, et al: Relationship of HHV8 replication and Kaposi’s sarcoma after solid organ transplantation. Transplantation 67:1200–1201, 1999.
Hudnall SD, Rady PL, Tyring SK, Fish JC: Hydrocortisone activation of human herpesvirus 8 viral DNA replication and gene expression in vitro. Transplantation 67:648–652, 1999.
Gao SJ, Zhang YJ, Deng JH, et al: Molecular polymorphism of Kaposi’s sarcoma-associated herpesvirus (human herpesvirus 8) latent nuclear antigen: Evidence for a large repertoire of viral genotypes and dual infection with different viral genotypes [published erratum appears in J Infect Dis 180(5):1756, 1999]. J Infect Dis 180:1466–1476, 1999.
Frances C, Mouquet C, Marcelin AG, et al: Outcome of kidney transplant recipients with previous human herpesvirus-8 infection [see comments]. Transplantation 69:1776–1779, 2000.
Regamey N, Cathomas G: HHV-8: A newly recognized pathogen in transplantation [comment]. Transplantation 69:1768–1769, 2000.
Neyts J, De Clercq E: Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 41:2754–2756, 1997.
Hammoud Z, Parenti DM, Simon GL: Abatement of cutaneous Kaposi’s sarcoma associated with cidofovir treatment [see comments]. Clin Infect Dis 26:1233, 1998.
Grossi P, Baldunti F, Corona A, et al: Kaposi sarcoma following thoracic organ transplantation: Prevalence, correlation with human herpesvirus 8 and new therapeutic options. Transplantation 67:S39, 1999.
Mozes MF, Ascher NL, Balfour HH Jr, Simmons RL, Najarian JS: Jaundice after renal allotransplantation. Ann Surg 188:783–790, 1978.
Haxhe JJ, Alexandre GP, Kestens PJ: The effect of imuran and azaserine on liver function tests in the dog. Its relation to the detection of graft rejection following liver transplantation. Arch Int Pharmacodyn Ther 168:366–372, 1967.
Starzl T, Marchioro T, Porter K, et al: Factors determining short and long-term survival after orthotopic liver homotransplantation. Surgery 58:131–155, 1965.
Sparberg M, Simon N, del Greco F: Intrahepatic cholestasis due to azathioprine. Gastroenterology 57:439–441, 1969.
Pirson Y, van Ypersele de Strihou C, Noel H, et al: Liver disease in transplanted patients. Proc EurDial Transplant Assoc 10:434–445, 1973.
Ware AJ, Luby JP, Hollinger B, et al: Etiology of liver disease in renal-transplant patients. Ann Intern Med 91:364–371, 1979.
Haboubi NY, Ali HH, Whitwell HL, Ackrill P: Role of endothelial cell injury in the spectrum of azathioprine-induced liver disease after renal transplant: Light microscopy and ultrastructural observations. Am J Gastmenterol 83:256–261, 1988.
Read AE, Wiesner RH, LaBrecque DR, et al: Hepatic venoocclusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med 104:651–655, 1986.
Katzka DA, Saul SH, Jorkasky D, et al: Azathioprine and hepatic venocclusive disease in renal transplant patients. Gastroenterology 90:446–454, 1986.
Norris SH, Butler TC, Glass N, Tran R: Fatal hepatic necrosis caused by disseminated type 5 adenovirus infection in a renal transplant recipient. Am J Nephrol 9:101–105, 1989.
Cames B, Rahier J, Burtomboy G, et al: Acute adenovirus hepatitis in liver transplant recipients. J Pediotr 120:33–37, 1992.
Gimson AE, White YS, Eddleston AL, Williams R: Clinical and prognostic differences in fulminant hepatitis type A, B and non-A non-B. Gut 24:1194–1198, 1983.
Szmuness W, Dienstag JL, Purcell RH, et al: Hepatitis type A and hemodialysis: A seroepidemiologic study in 15 U.S. centers. Ann Intern Med 87:8–12, 1977.
Barbara JA, Howell DR, Briggs M, Parry JV: Post-transfusion hepatitis A [letter]. Lancet 1:738, 1982.
Hollinger FB, Khan NC, Oefmger PE, et al: Posttransfusion hepatitis type A. JAMA 250:2313–2317, 1983.
Fagan E, Yousef G, Brahm J, et al: Persistence of hepatitis A virus in fulminant hepatitis and after liver transplantation. J Med Virol 30:131–136, 1990.
Robinson W: Hepatitis B virus and hepatitis delta virus. In Mandell G, Douglas RJ, Bennett J (eds): Principles and Practice of Infectious Diseases. Edinburgh, Churchill Livingstone, 1990, pp. 1204–1231.
Debure A, Degos F, Pol S, et al: Liver diseases and hepatic complications in renal transplant patients. Adv Nephrol Necker Hosp 17:375–400, 1988.
Rao KV, Kasiske BL, Anderson WR: Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation 51:391–396, 1991.
Luketic VA, Shiffman ML, McCall JB, et al: Primary hepatocellular carcinoma after orthotopic liver transplantation for chronic hepatitis B infection. Ann Intern Med 114:212–213, 1991.
Alter H: The chronic consequences of non-A, non-B hepatitis. In Seeff L, Lewis J (eds): Current Perspectives in Hepatology. New York, Plenum Press, 1989, pp. 83–97.
Service PH: Inter-Agency Guidelines for Screening Donors of Blood, Plasma, Organs, Tissues, and Semen for Evidence of Hepatitis B and Hepatitis C, 1991.
Rizzetto M: Hepatitis delta virus: Biology and infection. In Shikata T, Purcell R, Uchida T (eds): Virol Hepatitis C, D, and E. Amsterdam, Excerpta Medica, 1991, pp. 327–333.
Feinstone S: Non-A, non-B hepatitis. In Mandell G, Douglas RJ, Bennett J (eds): Principles and Practice of Infectious Diseases. Edinburgh, Churchill Livingstone, 1990, pp. 1407–1415.
Dusheiko G, Song E, Bowyer S, et al: Natural history of hepatitis B virus infection in renal transplant recipients—A fifteen-year follow-up. Hepatology 3:330–336, 1983.
Scott D, Mijch A, Lucas CR, et al: Hepatitis B and renal transplantation. Transplant Proc 19:2159–2160, 1987.
Stevens CE, Alter HJ, Taylor PE, et al: Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 311:496–501, 1984.
Jacobson IM, Jaffers G, Dienstag JL, et al: Immunogenicity of hepatitis B vaccine in renal transplant recipients. Transplantation 39:393–395, 1985.
Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T: Failure of hepatitis B immunization in liver transplant recipients: Results of a prospective trial. Am J Gastroenterol 85:1590–1592, 1990.
Nagington J: Reactivation of hepatitis B after transplantation operations. Lancet 1:558–560, 1977.
Scullard GH, Smith CI, Merigan TC, Robinson WS, Gregory PB: Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenlerology 81:987–991, 1981.
Lau JY, Bain VG, Smith HM, Alexander GJ, Williams R: Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture. Transplantation 53:894–898, 1992.
Cote PJ, Korba BE, Baldwin B, et al: Immunosuppression with cyclosporine during the incubation period of experimental woodchuck hepatitis virus infection increases the frequency of chronic infection in adult woodchucks. J Infect Dis 166:628–631, 1992.
Marinos G, Rossol S, Carucci P, et al: Immunopathogenesis of hepatitis B virus recurrence after liver transplantation. Transplantation 69:559–568, 2000.
Huang CC, Lai MK, Fong MT: Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation 49:540–544, 1990.
Parfrey PS, Forbes RD, Hutchinson TA, et al: The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 37:461–466, 1984.
Parfrey PS, Forbes RD, Hutchinson TA, et al: The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 39:610–615, 1985.
Weir MR, Kirkman RL, Strom TB, Tilney NL: Liver disease in recipients of long-functioning renal allografts. Kidney Int 28: 839–844, 1985.
Parfrey PS, Farge D, Forbes RD, et al: Chronic hepatitis in endstage renal disease: Comparison of HBsAg-negative and HBsAg-positive patients. Kidney Int 28:959–967, 1985.
Harnett JD, Zeldis JB, Parfrey PS, et al: Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation 44:369–376, 1987.
Rao KV, Andersen RC: Long-term results and complications in renal transplant recipients. Observations in the second decade. Transplantation 45:45–52, 1988.
Degos F, Lugassy C, Degott C, et al: Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. A prospective study of 90 patients. Gastroenterology 94:151–156, 1988.
Wedemeyer H, Pethig K, Wagner D, et al: Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 66:1347–1353, 1998.
Kim CM, Koike K, Saito I, Miyamura T, Jay G: HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 351:317–320, 1991.
Kekule AS, Lauer U, Weiss L, Luber B, Hofschneider PH: Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway [see comments]. Nature 361:742–745, 1993.
Sengar DP, Couture RA, Lazarovits AI, Jindal SL: Long-term patient and renal allograft survival in HBsAg infection: A recent update. Transplant Proc 21:3358–3359, 1989.
Fairley CK, Mijch A, Gust ID, et al: The increased risk of fatal liver disease in renal transplant patients who are hepatitis B antigen and/or HBV DNA positive. Transplantation 52:497–500, 1991.
Perrillo RP, Schiff ER, Davis GL, et al: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group [see comments]. N Engl J Med 323:295–301, 1990.
Kramer P, ten Kate FW, Bijnen AB, Jeekel J, Weimar W: Recombinant leucocyte interferon A induces steroid-resistant acute vascular rejection episodes in renal transplant recipients. Lancet 1:989–990, 1984.
Weimar W, Kramer P, Bijnen AB, et al: The incidence of cytomegalo-and herpes simplex virus infections in renal allograft recipients treated with high dose recombinant leucocyte interferon: A controlled study. Scand J Urol Nephrol Suppl 92:37–39, 1985.
Jain A, Demetris AJ, Manez R, et al: Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon. Liver Transplant Surg 4:197–203, 1998.
Kruger M, Tillmann HL, Trautwein C, et al: Famciclovir treatment of hepatitis B virus recurrence after liver transplantation: A pilot study. Liver Transplant Surg 2:253–262, 1996.
Singh N, Gayowski T, Wannstedt CF, Wagener MM, Marino IR: Pretransplant famciclovir as prophylaxis for hepatitis B virus recurrence after liver transplantation. Transplantation 63:1415–1419, 1997.
Wedemeyer H, Boker KH, Pethig K, et al: Famciclovir treatment of chronic hepatitis B in heart transplant recipients: A prospective trial. Transplantation 68:1503–1511, 1999.
Jurim O, Martin P, Winston DJ, et al: Failure of ganciclovir prophylaxis to prevent allograft reinfection following orthotopic liver transplantation for chronic hepatitis B infection. Liver Transplant Surg 2:370–374, 1996.
Rizzetto M, Mariano A: Posttransplantation prevention and treatment of recurrent hepatitis B [In Process Citation]. Liver Transplant 6:S47–S51, 2000.
Jarvis B, Faulds D: Lamivudine: A review of its therapeutic potential in chronic hepatitis B [published erratum appears in Drugs 58(4):587, 1999]. Drugs 58:101–141, 1999.
Ben-Ari Z, Shmueli D, Mor E, Shapira Z, Tur-Kaspa R: Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63:393–396, 1997.
Rostaing L, Henry S, Cisterne JM, et al: Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 64:1624–1637, 1997.
Al Faraidy K, Yoshida EM, Davis JE, Vartanian RK, Anderson FH: Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 64:926–928, 1997.
Jung YO, Lee YS, Yang WS, et al: Treatment of chronic hepatitis B with lamivudine in renal transplant recipients. Transplantation 66:733–737, 1998.
Andreone P, Caraceni P, Grazi GL, et al: Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol 29: 985–989, 1998.
Nery JR, Weppler D, Rodriguez M, et al: Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation. Transplantation 65:1615–1621, 1998.
Perrillo R, Rakela J, Dienstag J, et al: Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 29:1581–1586, 1999.
Mutimer D, Pillay D, Dragon E, et al: High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation. J Hepatol 30:715–721, 1999.
Bartholomew MM, Jansen RW, Jeffers LJ, et al: Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation [see comments]. Lancet 349:20–22, 1997.
Gauthier J, Bourne EJ, Lutz MW, et al: Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J Infect Dis 180: 1757–1762, 1999.
Seehofer D, Rayes N, Berg T, et al: Lamivudine as first-and second-line treatment of hepatitis B infection after liver transplantation [In Process Citation]. Transplant Int 13:290–296, 2000.
Puchhammer-Stockl E, Mandl CW, Kletzmayr J, et al: Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 181:2063–2066, 2000.
Fontaine H, Thiers V, Chretien Y, et al: HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation 69:2090–2094, 2000.
Peters MG, Singer G, Howard T, et al: Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 68:1912–1914, 1999.
Malkan G, Cattral MS, Humar A, et al: Lamivudine for hepatitis B in liver transplantation: A single-center experience. Transplantation 69:1403–1407, 2000.
Mutimer D, Dusheiko G, Barrett C, et al: Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Longterm follow-up. Transplantation 70:809–815, 2000.
Demetris AJ, Jaffe R, Sheahan DG, et al: Recurrent hepatitis B in liver allograft recipients. Differentiation between viral hepatitis B and rejection. Am J Pathol 125:161–172, 1986.
Portmann B, O’Grady J, Williams R: Disease recurrence following orthotopic liver transplantation. Transplant Proc 18(Suppl), 1986.
Freeman RB, Sanchez H, Lewis WD, et al: Serologic and DNA follow-up data from HBsAg-positive patients treated with orthotopic liver transplantation. Transplantation 51:793–797, 1991.
Levy GA, Sherker A, Fung LS, et al: Relevance of hepatitis B viral DNA in assessment of potential liver allograft recipients. Transplant Proc 21:3333–3334, 1989.
Demetris AJ, Todo S, Van Thiel DH, et al: Evolution of hepatitis B virus liver disease after hepatic replacement. Practical and theoretical considerations. Am J Pathol 137:667–676, 1990.
O’Grady JG, Smith HM, Davies SE, et al: Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 14:104–111, 1992.
Lavine JE, Lake JR, Ascher NL, et al: Persistent hepatitis B virus following interferon alfa therapy and liver transplantation. Gastroenterology 100:263–267, 1991.
Eason J, Freeman RJ, Rohrer R, et al: Should liver allograft transplantation be performed for patients with hepatitis B? Transplantation 70:397–401, 1994.
Samuel D, Bismuth A, Mathieu D, et al: Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 337:813–815, 1991.
Lauchart W, Muller R, Pichlmayr R: Long-termimmunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transplant Proc 19:4051–4053, 1987.
Grazi GL, Mazziotti A, Sama C, et al: Liver transplantation in HBsAg-positive HBV-DNA-Negative cirrhotics: Immunoprophylaxis and long-term outcome. Liver Transplant Surg 2:418–425, 1996.
Tchervenkov JI, Tector AJ, Barkun JS, et al: Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg 226:356–365; discussion 365–368, 1997.
Sawyer RG, McGory RW, Gaffey MJ, et al: Improved clinical outcomes with liver transplantation for hepatitis B-induced chronic liver failure using passive immunization. Ann Surg 227: 841–850, 1998.
Burbach GJ, Bienzle U, Neuhaus R, et al: Intravenous or intramuscular anti-HBs immunoglobulin for the prevention of hepatitis B reinfection after orthotopic liver transplantation. Transplantation 63:478–480, 1997.
Terrault NA, Zhou S, McCory RW, et al: Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 28:555–561, 1998.
Ghany MG, Ayola B, Villamil FG, et al: Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis [see comments]. Hepatology 27:213–222, 1998.
Carman WF, Owsianka A, Wallace LA, Dow BC, Mutimer DJ: Antigenic characterization of pre-and post-liver transplant hepatitis B surface antigen sequences from patients treated with hepatitis B immune globulin. J Hepatol 31:195–201, 1999.
Shields PL, Owsianka A, Carman WF, et al: Selection of hepatitis B surface “escape” mutants during passive immune prophylaxis following liver transplantation: Potential impact of genetic changes on polymerase protein function. Gut 45:306–309, 1999.
Santantonio T, Gunther S, Sterneck M, et al: Liver graft infection by HBV S-gene mutants in transplant patients receiving long-term HBIg prophylaxis. Hepatogastroenterology 46:1848–1854, 1999.
Tillmann HL, Trautwein C, Bock T, et al: Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under HBIg immunoglobulin after liver transplantation. Hepatology 30:244–256, 1999.
de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA: The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 29:669–675, 1998.
Markowitz JS, Martin P, Conrad AJ, et al: Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28:585–589, 1998.
Yoshida EM, Erb SR, Partovi N, et al: Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transplant Surg 5:520–525, 1998.
Bain V: Hepatitis B in transplantation. Transplant Infect Dis 2: 153–165, 2000.
Yao FY, Osorio RW, Roberts JP, et al: Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transplant Surg 5:491–496, 1999.
Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H: Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B [In Process Citation]. Liver Transplant 6:429–433, 2000.
McCaughan G, Zekry A: Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transplant Infect Dis 2:166–185, 2000.
Bruix J, Barrera JM, Calvet X, et al: Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis [see comments]. Lancet 2:1004–1006, 1989.
Yu MC, Tong MJ, Coursaget P, et al: Prevalence of hepatitis B and C viral markers in black and white patients with hepatocelllar carcinoma in the United States [see comments]. J Natl Cancer Inst 82:1038–1041, 1990.
Esteban JI, Lopez-Talavera JC, Genesca J, et al: High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus [see comments]. Ann Intern Med 115:443–449, 1991.
Kao JH, Chen PJ, Yang PM, el al: Intrafamilial transmission of hepatitis C virus: The important role of infections between spouses. J Infect Dis 166:900–903, 1992.
Prince AM, Brotman B, Inchauspe G, et al: Patterns and prevalence of hepatitis C virus infection in post-transfusion non-A, non-B hepatitis. J Infect Dis 167:1296–1301, 1993.
McCashland TM, Wright TL, Donovan JP, et al: Low incidence of intraspousal transmission of hepatitis C virus after liver transplantation. Liver Transplant Surg 1:358–361, 1995.
Wright TL, Hsu H, Donegan E, et al: Hepatitis C virus not found in fulminant non-A, non-B hepatitis [see comments]. Ann Intern Med 115:111–112, 1991.
Woodfield DG: Acute post-transfusion fulminant hepatitis C virus infection: A case report. Gastroenterol Jpn 26(Suppl 3):221–223, 1991.
Choo QL, Kuo G, Weiner AJ, Overby LR, et al: Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359–362, 1989.
Kuo G, Choo QL, Alter HJ, et al: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 244:362–364, 1989.
Alter HJ, Purcell RH, Shih JW, et al: Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 321:1494–1500, 1989.
Alter MJ, Hadler SC, Judson FN, et al: Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 264:2231–2235, 1990.
Roth D, Fernandez JA, Burke GW, Esquenazi V, Miller J: Detection of antibody to hepatitis C virus in renal transplant recipients. Transplantation 51:396–400, 1991.
Read AE, Donegan E, Lake J, et al: Hepatitis C in patients undergoing liver transplantation. Ann Intern Med 114:282–284, 1991.
Prince AM, Brotman B, Huima T, et al: Immunity in hepatitis C infection. J Infect Dis 165:438–443, 1992.
Farci P, London WT, Wong DC, et al: The natural history of infection with hepatitis C virus (HCV) in chimpanzees: Comparison of serologic responses measured with first-and second-generation assays and relationship to HCV viremia. J Infect Dis 165:1006–1011, 1992.
Preiksaitis JK, Cockfield SM, Fenton JM, Burton NI, Chui LW: Serologic responses to hepatitis C virus in solid organ transplant recipients. Transplantation 64:1775–1780, 1997.
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH: Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132:296–305, 2000.
LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al: Impact of hepatitis on renal transplantation. Transplantation 32:504–507, 1981.
Huang CC, Liaw YF, Lai MK, et al: The clinical outcome of hepatitis C virus antibody-positive renal allograft recipients. Transplantation 53:763–765, 1992.
Ponz E, Campistol JM, Bruguera M, et al: Hepatitis C virus infection among kidney transplant recipients. Kidney Int 40:748–751, 1991.
Hanafusa T, Ichikawa Y, Kishikawa H, et al: Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation 66:471–476, 1998.
Rostaing L, Izopet J, Cisterne JM, et al: Impact of hepatitis C virus duration and hepatitis C virus genotypes on renal transplant patients: Correlation with clinicopathological features. Transplantation 65:930–936, 1998.
Mathurin P, Mouquet C, Poynard T, et al: Impact of hepatitis B and C virus on kidney transplantation outcome [see comments]. Hepatology 29:257–263, 1999.
Chan TM, Lok AS, Cheng IK: Hepatitis C in renal transplant recipients. Transplantation 52:810–813, 1991.
Stempel CA, Lake J, Kuo G, Vincenti F: Hepatitis C—Its prevalence in end-stage renal failure patients and clinical course after kidney transplantation. Transplantation 55:273–276, 1993.
Knoll GA, Tankersley MR, Lee JY, Julian BA, Curtis JJ: The impact of renal transplantation on survival in hepatitis C-positive end-stage renal disease patients. Am J Kidney Dis 29:608–614, 1997.
Sterling RK, Sanyal AJ, Luketic VA, et al: Chronic hepatitis C infection in patients with end stage renal disease: Characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 94:3576–3582, 1999.
Rostaing L, Izopet J, Arnaud C, et al: Long-term impact of superinfection by hepatitis G virus in hepatitis C virus-positive renal transplant patients. Transplantation 67:556–560, 1999.
Muller H, Otto G, Goeser T, et al: Recurrence of hepatitis C virus infection after orthotopic liver transplantation. Transplantation 54:743–745, 1992.
Bouffard P, Hayashi PH, Acevedo R, et al: Hepatitis C virus is detected in a monocyte/macrophage subpopulation of peripheral blood mononuclear cells of infected patients. J Infect Dis 166: 1276–1280, 1992.
Boker KH, Dalley G, Bahr MJ, et al: Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology 25:203–210, 1997.
Feray C, Gigou M, Samuel D, et al: The course of hepatitis C virus infection after liver transplantation. Hepatology 20:1137–1143, 1994.
Gane EJ, Portmann BC, Naoumov NV, et al: Long-term outcome of hepatitis C infection after liver transplantation [see comments]. N Engl J Med 334:815–820, 1996.
Charlton M, Seaberg E, Wiesner R, et al: Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28:823–830, 1998.
Rosen HR, Martin P: Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 66:1612–1616, 1998.
Feray C, Caccamo L, Alexander GJ, et al: European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 117:619–625, 1999.
Magy N, Cribier B, Schmitt C, et al: Effects of corticosteroids on HCV infection. Int J Immunopharmacol 21:253–261, 1999.
Papatheodoridis GV, Barton SG, Andrew D, et al: Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: The role of different immunosuppressive regimens [see comments]. Gut 45:427–434, 1999.
Charlton M, Seaberg E: Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transplant Surg 5:S107–S114, 1999.
Rostaing L, Izopet J, Sandres K, et al: Changes in hepatitis C virus RNA viremia concentrations in long-term renal transplant patients after introduction of mycophenolate mofetil. Transplantation 69:991–994, 2000.
Rosen HR, Shackleton CR, Higa L, et al: Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation [see comments]. Am J Gastroenterol 92: 1453–1457, 1997.
Prieto M, Berenguer M, Rayon JM, et al: High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 29:250–256, 1999.
Cotler SJ, Gaur LK, Gretch DR, et al: Donor-recipient sharing of HLA class II alleles predicts earlier recurrence and accelerated progression of hepatitis C following liver transplantation. Tissue Antigens 52:435–443, 1998.
Neumann AU, Lam NP, Dahari H, et al: Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 182:28–35, 2000.
Pessoa MG, Bzowej N, Berenguer M, et al: Evolution of hepatitis C virus quasispecies in patients with severe cholestatic hepatitis after liver transplantation. Hepatology 30:1513–1520, 1999.
Rosen HR, Chou S, Corless CL, et al: Cytomegalovirus viremia: Risk factor for allograft cirrhosis after liver transplantation for hepatitis C. Transplantation 64:721–726, 1997.
Singh N, Zeevi A, Gayowski T, Marino IR: Late onset cytomegalovirus disease in liver transplant recipients: De novo reactivation in recurrent hepatitis C virus hepatitis. Transplant Int 11:308–311, 1998.
Weiss G, Umlauft F, Urbanek M, et al: Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 180:1452–1458, 1999.
Rosen HR, Lentz JJ, Rose SL, et al: Donor polymorphism of tumor necrosis factor gene: Relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 68:1898–1902, 1999.
Toth CM, Pascual M, Chung RT, et al: Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: Response to interferon-alpha therapy. Transplantation 66:1254–1258, 1998.
Delladetsima JK, Boletis JN, Makris F, et al: Fibrosing cholestatic hepatitis in renal transplant recipients with hepatitis C virus infection. Liver Transplant Surg 5:294–300, 1999.
Abraczinskas D, Chung R: Allograft dysfunction and hyperbilirubinemia in a liver transplant recipient. Transplant Infect Dis 2:186–193, 2000.
Davis CL, Gretch DR, Perkins JD, et al: Hepatitis C-associated glomerular disease in liver transplant recipients. Liver Transplant Surg 1:166–175, 1995.
Morales JM, Campistol JM, Andres A, Rodicio JL: Glomerular diseases in patients with hepatitis C virus infection after renal transplantation. Curr Opin Nephrol Hypertens 6:511–515, 1997.
Hestin D, Guillemin F, Castin N, et al: Pretransplant hepatitis C virus infection: A predictor of proteinuria after renal transplantation. Transplantation 65:741–744, 1998.
Pascual M, Thadhani R, Chung RT, et al: Nephrotic syndrome after liver transplantation in a patient with hepatitis C virus-associated glomerulonephritis. Transplantation 64:1073–1076, 1997.
Morales JM, Pascual-Capdevila J, Campistol JM, et al: Membranous glomerulonephritis associated with hepatitis C virus infection in renal transplant patients. Transplantation 63:1634–1639, 1997.
Cantarell MC, Charco R, Capdevila L, et al: Outcome of hepatitis C virus-associated membranoproliferative glomerulonephritis after liver transplantation [see comments]. Transplantation 68: 1131–1134, 1999.
Baid S, Cosimi AB, Tolkoff-Rubin N, et al: Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 70:255–261, 2000.
Singh N, Gayowski T, Wagener MM, Marino IR: Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 11:406–411, 1997.
Dickson RC, Wright RM, Bacchetta MD, et al: Quality of life of hepatitis B and C patients after liver transplantation. Clin Transplant 11:282–285, 1997.
Bona MD, Rupolo G, Ponton P, et al: The effect of recurrence of HCV infection on life after liver transplantation. Transplant Int 11:S475–S479, 1998.
Singh N, Gayowski T, Wagener MM, Marino IR: Quality of life, functional status, and depression in male liver transplant recipients with recurrent viral hepatitis C. Transplantation 67:69–72, 1999.
Management of hepatitis C. NIH Consensus Statement 15:1–41, 1997.
Sheiner PA, Boros P, Klion FM, et al: The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 28:831–838, 1998.
Cattral MS, Hemming AW, Wanless IR, et al: Outcome of longterm ribavirin therapy for recurrent hepatitis C after liver transplantation. Transplantation 67:1277–1280, 1999.
Bizollon T, Palazzo U, Ducerf C, et al: Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation [see comments]. Hepatology 26:500–504, 1997.
Muramatsu S, Ku Y, Fukumoto T, et al: Successful rescue of severe recurrent hepatitis C with interferon and ribavirin in a liver transplant patient. Transplantation 69:1956–1958, 2000.
Zeuzem S, Feinman SV, Rasenack J, et al: Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343:1666–1672, 2000.
Heathcote EJ, Shiffman ML, Cooksley WG, et al: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343:1673–1680, 2000.
Tzakis AG, Cooper MH, Dummer JS, et al: Transplantation in HIV+ patients. Transplantation 49:354–358, 1990.
Erice A, Rhame FS, Heussner RC, Dunn DL, Balfour HH Jr: Human immunodeficiency virus infection in patients with solid-organ transplants: Report of five cases and review [see comments]. Rev Infect Dis 13:537–547, 1991.
Patijn GA, Strengers PF, Harvey M, Persijn G: Prevention of transmission of HIV by organ and tissue transplantation. HIV testing protocol and a proposal for recommendations concerning donor selection. Transplant Int 6:165–172, 1993.
Rubin RH, Jenkins RL, Shaw BW Jr, et al: The acquired immunodeficiency syndrome and transplantation. Transplantation 44:1–4, 1987.
Ahuja TS, Zingman B, Glicklich D: Long-term survival in an HIV-infected renal transplant recipient. Am J Nephrol 17:480–482, 1997.
Purgus R, Tamalet C, Poignard P, et al: Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient. Transplantation 66:1384–1386, 1998.
Hogg RS, Heath KV, Yip B, et al: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [see comments]. JAMA 279:450–454, 1998.
Palella FJ Jr, Delaney KM, Moorman AC, et al: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. N Engl J Med 338:853–860, 1998.
Spital A: Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation 65:1187–1191, 1998.
Schvarcz R, Rudbeck G, Soderdahl G, Stahle L: Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). Transplantation 69:2194–2195, 2000.
Gout O, Baulac M, Gessain A, et al: Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med 322:383–388, 1990.
Sullivan MT, Williams AE, Fang CT, et al: Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). The American Red Cross HTLV-I/II Collabomtive Study Group. Arch Intern Med 151:2043–2048, 1991.
Perez G, Ortiz-Interian C, Bourgoignie JJ, et al: HIV-1 and HTLV-I infection in renal transplant recipients. J Acquir Immune Defic Syndr 3:35–40, 1990.
Garner S: Prevalence in England of antibody to polyomavirus (B.K.). Br Med J 1:77–78, 1973.
Shah KV, Daniel RW, Warszawski RM: High prevalence of antibodies to BK virus, an SV40-related papovavirus, in residents of Maryland. J Infect Dis 128:784–787, 1973.
Brown P, Tsai T, Gajdusek DC: Seroepidemiology of human papovaviruses. Discovery of virgin populations and some unusual patterns of antibody prevalence among remote peoples of the world. Am J Epidemiol 102:331–340, 1975.
Gardner SD, Field AM, Coleman DV, Hulme B: New human papovavirus (B.K.) isolated from urine after renal transplantation. Lancet 1:1253–1257, 1971.
Coleman DV, Gardner SD, Field AM: Human polyomavirus infection in renal allograft recipients. Br Med J 3:371–375, 1973.
Lecatsas G, Prozesky OW, Wyk Jv, Els HJ: Papova virus in urine after renal transplantation. Nature 241:343–344, 1973.
Shah KV, Daniel RW, Zeigel RF, Murphy GP: Search for BK and SV40 virus reactivation in renal transplant recipients. Transplantation 17:131–134, 1974.
Flower AJ, Banatvala JE, Chrystie IL: BK antibody and virus-specific IgM responses in renal transplant recipients, patients with malignant disease, and healthy people. Br Med J 2:220–223, 1977.
Coleman DV, Mackenzie EF, Gardner SD, et al: Human polyomavirus (BK) infection and ureteric stenosis in renal allograft recipients. J Clin Pathol 31:338–347, 1978.
Cheeseman SH, Black PH, Rubin RH, Cantell K, Hirsch MS: Interferon and BK papovavirus—Clinical and laboratory studies. J Infect Dis 141:157–161, 1980.
Hogan TF, Borden EC, McBain JA, Padgett BL, Walker DL: Human polyomavirus infections with JC virus and BK virus in renal transplant patients. Ann Intern Med 92:373–378, 1980.
Narayan O, Penney JB Jr, Johnson RT, Herndon RM, Weiner LP: Etiology of progressive multifocal leukoencephalopathy. Identification of papovavirus. N Engl J Med 289:1278–1282, 1973.
Padgett B, Walker D: New human papovaviruses. In Melnick J (ed): Progress in Medical Virology. Basel, Karger, 1976, pp. 1–35.
Andrews CA, Shah KV, Daniel RW, Hirsch MS, Rubin RH: A serological investigation of BK virus and JC virus infections in recipients of renal allografts. J Infect Dis 158:176–181, 1988.
Flaegstad T, Nilsen I, Skar AG, Traavik T: Antibodies against BK virus in renal transplant recipient sera: Results with five different methods indicate frequent reactivations. Scand J Infect Dis 23:287–291, 1991.
Boubenider S, Hiesse C, Marchand S, et al: Post-transplantation polyomavirus infections. J Nephrol 12:24–29, 1999.
Howell DN, Smith SR, Butterly DW, et al: Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 68:1279–1288, 1999.
Binet I, Nickeleit V, Hirsch HH, et al: Polyomavirus disease under new immunosuppressive drugs: A cause of renal graft dysfunction and graft loss. Transplantation 67:918–922, 1999.
Leventhal B, Soave R, Mouradian J, Cheigh J: Renal dysfunction and hyperglycemia in a renal transplant recipient. Transplant Infect Dis 1:288–294, 1999.
Padgett BL, Walker DL, ZuRhein GM, et al: Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy. Lancet 1:1257–1260, 1971.
Wolfson JS, Sober AJ, Rubin RH: Dermatologic manifestations of infections in immunocompromised patients. Medicine 64:115–133, 1985.
Koranda FC, Dehmel EM, Kahn G, Penn I: Cutaneous complications in immunosuppressed renal homograft recipients. JAMA 229:419–424, 1974.
Mullen D, Silverberg S, Penn I, et al: Squamous cell carcinoma of the skin and lip in renal homograft recipients. JAMA 229:729–734, 1976.
Savin JA, Noble WC: Immunosuppression and skin infection. Br J Dermatol 93:115–120, 1975.
Lutzner MA, Orth G, Dutronquay V, et al: Detection of human papillomavirus type 5 DNA in skin cancers of an immunosup-pressed renal allograft recipient. Lancet 2:422–424, 1983.
Ostrow RS, Bender M, Niimura M, et al: Human papillomavirus DNA in cutaneous primary and metastasized squamous cell carcinomas from patients with epidermodysplasia verruciformis. Proc Natl Acad Sci USA 79:1634–1638, 1982.
Barr BB, Benton EC, McLaren K, et al: Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1:124–129, 1989.
Hopfl R, Bens G, Wieland U, et al: Human papillomavirus DNA in non-melanoma skin cancers of a renal transplant recipient: Detection of a new sequence related to epidermodysplasia verruciformis associated types. J Invest Dermatol 108:53–56, 1997.
Arends MJ, Benton EC, McLaren KM, et al: Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 75:722–728, 1997.
Bens G, Wieland U, Hofmann A, Hopfl R, Pfister H: Detection of new human papillomavirus sequences in skin lesions of a renal transplant recipient and characterization of one complete genome related to epidermodysplasia verruciformis-associated types. J Gen Virol 79:779–787, 1998.
de Jong-Tieben LM, Berkhout RJ, ter Schegget J, et al: The prevalence of human papillomavirus DNA in benign keratotic skin lesions of renal transplant recipients with and without a history of skin cancer is equally high: A clinical study to assess risk factors for keratotic skin lesions and skin cancer. Transplantation 69:44–49, 2000.
Alloub MI, Barr BB, McLaren KM, et al: Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. Br Med J 298:153–156, 1989.
Leptak C, Ramon y Cajal S, Kulke R, et al: Tumorigenic transformation of murine keratinocytes by the E5 genes of bovine papillomavirus type 1 and human papillomavirus type 16 [published erratum appears in J Virol 66(3):1833, 1992]. J Virol 65:7078–7083, 1991.
Hinman F Jr, Schmaelzle JF, Belzer FO: Urinary tract infection and renal homotransplantation. II. Post-transplantation bacterial invasion. J Urol 101:673–679, 1969.
Leigh DA: The outcome of urinary tract infections in patients after human cadaveric renal transplantation. Br J Urol 41:406–413, 1969.
Martin DC: Urinary tract infection in clinical renal transplantation. Arch Surg 99:474–476, 1969.
Prout GR Jr, Hume DM, Williams GM, Lee HM: Some urological aspects of 93 consecutive renal homotransplants in modified recipients. J Urol 97:409–425, 1967.
Ramsey DE, Finch WT, Birtch AG: Urinary tract infections in kidney transplant recipients. Arch Surg 114:1022–1025, 1979.
Rubin RH, Fang LS, Cosimi AB, et al: Usefulness of the antibody-coated bacteria assay in the management of urinary tract infection in the renal transplant patient. Transplantation 27:18–20, 1979.
Myerowitz RL, Medeiros AA, O’Brien TF: Bacterial infection in renal homotransplant recipients. A study of fifty-three bacteremic episodes. Am J Med 53:308–314, 1972.
Nielsen HE, Korsager B: Bacteremia after renal transplantation. Scand J Infect Dis 9:111–117, 1977.
Pearson JC, Amend WJ Jr, Vincenti FG, Feduska NJ, Salvatierra O Jr: Post-transplantation pyelonephritis: Factors producing low patient and transplant morbidity. J Urol 123:153–156, 1980.
Burleson RL, Brennan AM, Scruggs BF: Foley catheter tip cultures: A valuable diagnostic aid in the immunosuppressed patient. Am J Surg 133:723–725, 1977.
Schaeffer AJ: Catheter-associated bacteriuria in patients in reverse isolation. J Urol 128:752–754, 1982.
Schaeffer AJ, Chmiel J: Urethral meatal colonization in the pathogenesis of catheter-associated bacteriuria. J Urol 130:1096–1099, 1983.
Hepinstall R: Experimental pyelonephritis: A comparison of blood-borne and ascending patterns of infection. J Pathol 89:71–80, 1965.
Tolkoff-Rubin NE, Rubin RH: Urinary tract infection in the immunocompromised host. Lessons from kidney transplantation and the AIDS epidemic. Infect Dis Clin North Am 11:707–717, 1997.
Tolkoff-Rubin N, Cosimi A, Russell P, et al: A controlled study of trimethoprim-sulfamethoxazole prophylaxis of urinary tract infections in renal transplant recipients. Rev Infect Dis 4:614–618, 1982.
Fox BC, Sollinger HW, Belzer FO, Maki DG: A prospective, randomized, double-blind study of trimethoprim-sulfamethox-azole for prophylaxis of infection in renal transplantation: Clinical efficacy, absorption of trimethoprim-sulfamethoxazole, effects on the microflora, and the cost-benefit of prophylaxis. Am J Med 89:255–274, 1990.
Maki DG, Fox BC, Kuntz J, Sollinger HW, Belzer FO: A prospective, randomized, double-blind study of trimethoprim-sulfamethoxazole for prophylaxis of infection in renal transplantation. Side effects of trimethoprim-sulfamethoxazole, interaction with cyclosporine. J Lab Clin Med 119:11–24, 1992.
Hibberd P, Tolkoff-Rubin N, Doran M, et al: Trimethoprim-sulfamethoxazole compared with ciprofloxacin for the prevention of urinary tract infection in renal transplant recipients. Online: J Curr Clin Trials Doc. #15, 1992.
Hibberd PL, Rubin RH: Approach to immunization in the immunosuppressed host. Infect Dis Clin North Am 4:123–142, 1990.
Cosimi AB, Colvin RB, Burton RC, et al: Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 305:308–314, 1981.
Peigue-Lafeuille H, Gazuy N, Mignot P, et al: Severe respiratory syncytial virus pneumonia in an adult renal transplant recipient: Successful treatment with ribavirin. Scand J Infect Dis 22:87–89, 1990.
Doud JR, Hinkamp T, Garrity ER Jr: Respiratory syncytial virus pneumonia in a lung transplant recipient: Case report. J Heart Lung Transplant 11:77–79, 1992.
Hierholzer JC, Atuk NO, Gwaltney JM Jr: New human adenovirus isolated from a renal transplant recipient: Description and characterization of candidate adenovirus type 34. J Clin Microbiol 1:366–376, 1975.
Myerowitz RL, Stalder H, Oxman MN, et al: Fatal disseminated adenovirus infection in a renal transplant recipient. Am J Med 59:591–598, 1975.
Keller EW, Rubin RH, Black PH, Hirsch MS, Hierholzer JC: Isolation of adenovirus type 34 from a renal transplant recipient with interstitial pneumonia. Transplantation 23:188–191, 1977.
Stalder H, Hierholzer JC, Oxman MN: New human adenovirus (candidate adenovirus type 35) causing fatal disseminated infection in a renal transplant recipient. J Clin Microbiol 6:257–265, 1977.
Lecatsas G, Prozesky OW, van Wyk J: Letter: Adenovirus type II associated with haemorrhagic cystitis after renal transplantation. S Afr Med J 48:1932, 1974.
Harnett GB, Bucens MR, Clay SJ, Saker BM: Acute haemorrhagic cystitis caused by adenovirus type 11 in a recipient of a transplanted kidney. Med J Aust 1:565–567, 1982.
Huebner R, Rowe W, Lane WT: Oncogenic effects in hamsters of human adenoviruses types 12 and 18. Proc Natl Acad Sci USA 48:2051–2058, 1962.
Koneru B, Jaffe R, Esquivel CO, et al: Adenoviral infections in pediatric liver transplant recipients. JAMA 258:489–492, 1987.
Yagisawa T, Takahashi K, Yamaguchi Y, et al: Adenovirus induced nephropathy in kidney transplant recipients. Transplant Proc 21:2097–2099, 1989.
Wreghitt TG, Gray JJ, Ward KN, et al: Disseminated adenovirus infection after liver transplantation and its possible treatment with ganciclovir [letter]. J Infect 19:88–89, 1989.
Hall WA, Martinez AJ, Dummer JS, et al: Central nervous system infections in heart and heart-lung transplant recipients. Arch Neurol 46:173–177, 1989.
Tolkoff-Rubin N, Hovingh G, Rubin R: Central nervous system infections. In Wijdicks E (ed): Neurologic Complications in Organ Transplant Recipients. Boston, Butterworth Heinemann, 1999, pp. 141–168.
Singh N, Husain S: Infections of the central nervous system in transplant recipients. Transplant Infect Dis 2:101–111, 2000.
de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA: Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 317:861–866, 1987.
Wijdicks E: Neurologic manifestations of immunosuppressive agents. In Wijdicks E (ed): Neurologic Complications in Organ Transplant Recipients. Boston, Butterworth Heinemann, 1999, pp. 127–140.
Ryning FW, McLeod R, Maddox JC, Hunt S, Remington JS: Probable transmission of Toxoplasma gondii by organ transplantation. Ann Intern Med 90:47–49, 1979.
Luft BJ, Naot Y, Araujo FG, Stinson EB, Remington JS: Primary and reactivated toxoplasma infection in patients with cardiac transplants. Clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med 99:27–31, 1983.
Rose AG, Uys CJ, Novitsky D, Cooper DK, Barnard CN: Toxoplasmosis of donor and recipient hearts after heterotopic cardiac transplantation. Arch Pathol Lab Med 107:368–373, 1983.
McGregor CG, Fleck DG, Nagington J, et al: Disseminated toxoplasmosis in cardiac transplantation. J Clin Pathol 37:74–77, 1984.
Nagington J, Martin AL: Toxoplasmosis and heart transplantation [letter]. Lancet 2:679, 1983.
Hakim M, Esmore D, Wallwork J, English TA, Wreghitt T: Toxoplasmosis in cardiac transplantation. Br Med J (Clin Res Ed) 292:1108, 1986.
Britt RH, Enzmann DR, Remington JS: Intracranial infection in cardiac transplant recipients. Ann Neurol 9:107–119, 1981.
Luft BJ, Billingham M, Remington JS: Endomyocardial biopsy in the diagnosis of toxoplasmic myocarditis. Transplant Proc 18:1871–1873, 1986.
Michaels MG, Wald ER, Fricker FJ, del Nido PJ, Armitage J: Toxoplasmosis in pediatric recipients of heart transplants. Clin Infect Dis 14:847–851, 1992.
Wreghitt TG, Gray JJ, Pavel P, et al: Efficacy of pyrimethamine for the prevention of donor-acquired Toxoplasma gondii infection in heart and heart-lung transplant patients. Transplant Int 5:197–200, 1992.
Conti DJ, Rubin RH: Infection of the central nervous system in organ transplant recipients. Neurol Clin 6:241–260, 1988.
Ascher NL, Simmons RL, Marker S, Najarian JS: Listeria infection in transplant patients. Five cases and a review of the literature. Arch Surg 113:90–94, 1978.
Schroter GP, Weil RD: Listeria monocytogenes infection after renal transplantation. Arch Intern Med 137:1395–1399, 1977.
Niklasson PM, Hambraeus A, Lundgren G, et al: Listeria encephalitis in five renal transplant recipients. Acta Med Scand 203:181–185, 1978.
Tilney NL, Kohler TR, Strom TB: Cerebromeningitis in immunosuppressed recipients of renal allografts. Ann Surg 195:104–109, 1982.
Armstrong RW, Fung PC: Brainstem encephalitis (rhombencephalitis) due to Listeria monocytogenes: Case report and review. Clin Infect Dis 16:689–702, 1993.
Stamm AM, Smith SH, Kirklin JK, McGiffin DC: Listerial myocarditis in cardiac transplantation. Rev Infect Dis 12:820–823, 1990.
MacGowan AP, Marshall RJ, MacKay IM, Reeves DS: Listeria faecal carriage by renal transplant recipients, haemodialysis patients and patients in general practice: Its relation to season, drug therapy, foreign travel, animal exposure and diet. Epidemiol Infect 106:157–166, 1991.
Gaillard JL, Berche P, Frehel C, Gouin E, Cossart P: Entry of L. monocytogenes into cells is mediated by internalin, a repeat protein reminiscent of surface antigens from gram-positive cocci. Cell 65:1127–1141, 1991.
Schlech WFd, Lavigne PM, Bortolussi RA, et al: Epidemic listeriosis—Evidence for transmission by food. N Engl J Med 308:203–206, 1983.
Watson GW, Fuller TJ, Elms J, Kluge RM: Listeria cerebritis: Relapse of infection in renal transplant patients. Arch Intern Med 138:83–87, 1978.
Larner AJ, Conway MA, Mitchell RG, Forfar JC: Recurrent Listeria monocytogenes meningitis in a heart transplant recipient. J Infect 19:263–266, 1989.
Peetermans WE, Endtz HP, Janssens AR, van den Broek PJ: Recurrent Listeria monocytogenes bacteraemia in a liver transplant patient. Infection 18:107–108, 1990.
Moellering RC Jr, Medoff G, Leech I, Wennersten C, Kunz LJ: Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother 1:30–34, 1972.
Scheer MS, Hirschman SZ: Oral and ambulatory therapy of Listeria bacteremia and meningitis with trimethoprim-sulfa-methoxazole. Mt Sinai J Med 49:411–414, 1982.
Spitzer PG, Hammer SM, Karchmer AW: Treatment of Listeria monocytogenes infection with trimethoprim-sulfamethoxazole: Case report and review of the literature. Rev Infect Dis 8:427–430, 1986.
Agarwal A, Gupta A, Sakhuja V, et al: Retinitis following disseminated cryptococcosis in a renal allograft recipient. Efficacy of oral fluconazole. Acta Ophthalmol 69:402–405, 1991.
Schroter GP, Temple DR, Husberg BS, Weid RD, Starzl TE: Cryptococcosis after renal transplantation: Report of ten cases. Surgery 79:268–277, 1976.
Ellner JJ, Bennett JE: Chronic meningitis. Medicine 55:341–369, 1976.
Bennett JE, Dismukes WE, Duma RJ, et al: A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301:126–131, 1979.
Hellman RN, Hinrichs J, Sicard G, et al: Cryptococcal pyelonephritis and disseminated cryptococcosis in a renal transplant recipient. Arch Intern Med 141:128–130, 1981.
Plunkett JM, Turner BI, Tallent MB, Johnson HK: Cryptococcal septicemia associated with urologic instrumentation in a renal allograft recipient. J Urol 125:241–242, 1981.
Conti DJ, Tolkoff-Rubin NE, Baker GP Jr, et al: Successful treatment of invasive fungal infection with fluconazole in organ transplant recipients. Transplantation 48:692–695, 1989.
Weiland D, Ferguson RM, Peterson PK, et al: Aspergillosis in 25 renal transplant patients. Epidemiology, clinical presentation, diagnosis, and management. Ann Surg 198:622–629, 1983.
Montero CG, Martinez AJ: Neuropathology of heart transplantation: 23 cases. Neurology 36:1149–1154, 1986.
Green M, Wald ER, Tzakis A, Todo S, Starzl TE: Aspergillosis of the CNS in a pediatric liver transplant recipient: Case report and review. Rev Infect Dis 13:653–657, 1991.
Rubin R, Weinstein L: Salmonellosis: Microbiologic, Pathologic and Clinical Features. New York, Stratton Intercontinental, 1977.
Smith EJ, Milligan SL, Filo RS: Salmonella mycotic aneurysm after renal transplantation. South Med J 74:1399–1401, 1981.
Berk MR, Meyers AM, Cassal W, Botha JR, Myburgh JA: Non-typhoid salmonella infections after renal transplantation. A serious clinical problem. Nephron 37:186–189, 1984.
Samra Y, Snaked Y, Maier MK: Nontyphoid salmonellosis in renal transplant recipients: Report of five cases and review of the literature. Rev Infect Dis 8:431–440, 1986.
Dhar JM, al-Khader AA, al-Sulaiman M, al-Hasani MK: Non-typhoid salmonella in renal transplant recipients: A report of twenty cases and review of the literature. Q J Med 78:235–250, 1991.
Wade JJ, Rolando N, Hayllar K, et al: Bacterial and fungal infections after liver transplantation: An analysis of 284 patients. Hepatology 21:1328–1336, 1995.
Patel R, Badley AD, Larson-Keller J, et al: Relevance and risk factors of enterococcal bacteremia following liver transplantation. Transplantation 61:1192–1197, 1996.
George DL, Arnow PM, Fox A, et al: Patterns of infection after pediatric liver transplantation. Am J Dis Child 146:924–929, 1992.
King RW Jr, Kraikitpanitch S, Lindeman RD: Subcutaneous nodules caused by Histoplasma capsulatum [letter]. Ann Intern Med 86:586–587, 1977.
Kauffman CA, Israel KS, Smith JW, et al: Histoplasmosis in immunosuppressed patients. Am J Med 64:923–932, 1978.
Davies SF, Khan M, Sarosi GA: Disseminated histoplasmosis in immunologically suppressed patients. Occurrence in a non-endemic area. Am J Med 64:94–100, 1978.
Davies SF, Sarosi GA, Peterson PK, et al: Disseminated histoplasmosis in renal transplant recipients. Am J Surg 137:686–691, 1979.
Peterson PK, Dahl MV, Howard RJ, Simmons RL, Najarian JS: Mucormycosis and cutaneous histoplasmosis in a renal transplant recipient. Arch Dermatol 118:275–277, 1982.
Deresinski SC, Stevens DA: Coccidioido-mycosis in compromised hosts. Experience at Stanford University Hospital. Medicine 54:377–395, 1975.
Bayer AS, Yoshikawa TT, Galpin JE, Guze LB: Unusual syndromes of Coccidioidomycosis: Diagnostic and therapeutic considerations: A report of 10 cases and review of the English literature. Medicine 55:131–152, 1976.
Schroter GP, Bakshandeh K, Husberg BS, Well RD: Coccidioidomycosis and renal transplantation. Transplantation 23:485–489, 1977.
Cohen IM, Galgiani JN, Potter D, Ogden DA: Coccidioidomycosis in renal replacement therapy. Arch Intern Med 142:489–494, 1982.
Gallis HA, Berman RA, Cate TR, et al: Fungal infection following renal transplantation. Arch Intern Med 135:1163–1172, 1975.
Serody JS, Mill MR, Detterbeck FC, Harris DT, Cohen MS: Blastomycosis in transplant recipients: Report of a case and review. Clin Infect Dis 16:54–58, 1993.
Mayer JM, Nimer L, Carroll K: Isolated pulmonary aspergillar infection in cardiac transplant recipients: Case report and review. Clin Infect Dis 15:698–700, 1992.
Sridhar NR, Tchervenkov JI, Weiss MA, Hijazi YM, First MR: Disseminated histoplasmosis in a renal transplant patient: A cause of renal failure several years following transplantation. Am J Kidney Dis 17:719–721, 1991.
Benedict LM, Kusne S, Torre-Cisneros J, Hunt SJ: Primary cutaneous fungal infection after solid-organ transplantation: Report of five cases and review [see comments]. Clin Infect Dis 15:17–21, 1992.
Durand F, Bernuau J, Dupont B, et al: Aspergillus intraabdominal abscess after liver transplantation successfully treated with itraconazole. Transplantation 54:734–735, 1992.
Kusne S, Torre-Cisneros J, Manez R, et al: Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis 166: 1379–1383, 1992.
Le Conte P, Blanloeil Y, Michel P, Francois T, Paineau J: Cutaneous aspergillosis in a patient with orthotopic hepatic transplantation. Transplantation 53:1153–1154, 1992.
Rattazzi LC, Simmons RL, Spanos PK, Bradford DS, Najarian JS: Successful management of miliary tuberculosis after renal transplantation. Am J Surg 130:359–361, 1975.
Oliver WA: Tuberculosis in renal transplant patients. Med J Aust 1:828–829, 1976.
Bell TJ, Williams GB: Successful treatment of tuberculosis in renal transplant recipients. J R Soc Med 71:265–268, 1978.
Ascher NL, Simmons RL, Marker S, Klugman J, Najarian JS: Tuberculous joint disease in transplant patients. Am J Surg 135:853–856, 1978.
Riska H, Kuhlback B: Tuberculosis and kidney transplantation. Acta Med Scand 205:637–640, 1979.
Vaz AJ: Miliary tuberculosis and the adult respiratory distress syndrome in a renal transplant recipient [letter]. Chest 75:412, 1979.
Lloveras J, Peterson PK, Simmons RL, Najarian JS: Mycobacterial infections in renal transplant recipients. Seven cases and a review of the literature. Arch Intern Med 142:888–892, 1982.
Coutts, II, Jegarajah S, Stark JE: Tuberculosis in renal transplant recipients. Br J Dis Chest 73:141–148, 1979.
Spence RK, Dafoe DC, Rabin G, et al: Mycobacterial infections in renal allograft recipients. Arch Surg 118:356–359, 1983.
Qunibi WY, al-Sibai MB, Taher S, et al: Mycobacterial infection after renal transplantation—Report of 14 cases and review of the literature. Q J Med 77:1039–1060, 1990.
al-Sulaiman MH, Dhar JM, al-Hasani MK, Haleem A, Al-Khader A: Tuberculous interstitial nephritis after kidney transplantation. Transplantation 50:162–164, 1990.
Higgins RM, Cahn AP, Porter D, et al: Mycobacterial infections after renal transplantation. Q J Med 78:145–153, 1991.
Sterneck M, Ferrell L, Ascher N, et al: Mycobacterial infection after liver transplantation: A report of three cases and review of the literature. Clin Transplant 6:55–61, 1992.
Sundberg R, Shapiro R, Darras F, et al: A tuberculosis outbreak in a renal transplant program. Transplant Proc 23:3091–3092, 1991.
Horsburgh CR Jr, Feldman S, Ridzon R: Practice guidelines for the treatment of tuberculosis [In Process Citation]. Clin Infect Dis 31:633–639, 2000.
Thomas PA Jr, Mozes MF, Jonasson O: Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 114:597–599, 1979.
Higgins R, Kusne S, Reyes J, et al: Mycobacterium tuberculosis after liver transplantation: Management and guidelines for prevention. Clin Transplant 6:81–90, 1992.
Meyers BR, Papanicolaou GA, Sheiner P, Emre S, Miller C: Tuberculosis in orthotopic liver transplant patients: Increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 69:64–69, 2000.
Novick RJ, Moreno-Cabral CE, Stinson EB, et al: Nontuberculous mycobacterial infections in heart transplant recipients: A seventeen-year experience. J Heart Transplant 9:357–363, 1990.
Cruz N, Ramirez-Muxo O, Bermudez RH, Santiago-Delpin EA: Pulmonary infection with M. kansasii in a renal transplant patient. Nephron 26:187–188, 1980.
Bolivar R, Satterwhite TK, Floyd M: Cutaneous lesions due to Mycobacterium kansasii. Arch Dermatol 116:207–208, 1980.
Trulock EP, Bolman RM, Genton R: Pulmonary disease caused by Mycobacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis 140:802–805, 1989.
Weber J, Mettang T, Staerz E, Machleidt C, Kuhlman U: Pulmonary disease due to Mycobacterium xenopi in a renal allograft recipient: Report of a case and review. Rev Infect Dis 11:964–969, 1989.
Gombert ME, Goldstein EJ, Corrado ML, Stein AJ, Butt KM: Disseminated Mycobacterium marinum infection after renal transplantation. Ann Intern Med 94:486–487, 1981.
Davis BR, Brumbach J, Sanders WJ, Wolinsky E: Skin lesions caused by Mycobacterium haemophilum. Ann Intern Med 97: 723–724, 1982.
Neeley SP, Denning DW: Cutaneous Mycobacterium thermoresistibile infection in a heart transplant recipient. Rev Infect Dis 11:608–611, 1989.
Heironimus JD, Winn RE, Collins CB: Cutaneous nonpulmonary Mycobacterium chelonei infection. Successful treatment with sulfonamides in an immunosuppressed patient. Arch Dermatol 120:1061–1063, 1984.
Cooper JF, Lichtenstein MJ, Graham BS, Schaffner W: Mycobacterium chelonae: A cause of nodular skin lesions with a proclivity for renal transplant recipients. Am J Med 86:173–177, 1989.
Kochhar R, Indudhara R, Nagi B, Yadav RV, Mehta SK: Colonic tuberculosis due to atypical mycobacteria in a renal transplant recipient [letter]. Am J Gastroenterol 83:1435–1436, 1988.
Patel R, Roberts GD, Keating MR, Paya CV: Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 19:263–273, 1994.
Munoz RM, Alonso-Pulpon L, Yebra M, et al: Intestinal involvement by nontuberculous mycobacteria after heart transplantation. Clin Infect Dis 30:603–605, 2000.
Diagnosis and treatment of disease caused by nontuberculous mycobacteria [published erratum appears in Am Rev Respir Dis 143(1)204, 1991] [see comments]. Am Rev Respir Dis 142:940–953, 1990.
Burroughs M, Moscone A: Immunization of pediatric solid organ transplant candidates and recipients. Clin Infect Dis 30:857–869, 2000.
Loinaz C, de Juanes JR, Gonzalez EM, et al: Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 44:235–238, 1997.
Blumberg EA, Albano C, Pruett T, et al: The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 22:295–302, 1996.
Admon D, Engelhard D, Strauss N, Goldman N, Zakay-Rones Z: Antibody response to influenza immunization in patients after heart transplantation. Vaccine 15:1518–1522, 1997.
Blumberg EA, Fitzpatrick J, Stutman PC, Hayden F, Brozena SC: Safety of influenza vaccine in heart transplant recipients. J Heart Lung Transplant 17:1075–1080, 1998.
Gershon AA: Immunizations for pediatric transplant patients. Kidney Int Suppl 43:S87–S90, 1993.
Pediatrics AAo: Poliovirus infections. In Georges M (ed): Red Book: Report of the Committee on Infectious Disease. Elk Grove Village, IL, American Academy of Pediatrics, 1997, pp. 424–433.
Nkowane BM, Wassilak SG, Orenstein WA, et al: Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA 257:1335–1340, 1987.
Zamora I, Simon JM, Da Silva ME, Piqueras AI: Attenuated varicella virus vaccine in children with renal transplants. Pediatr Nephrol 8:190–192, 1994.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
Rubin, R.H. (2002). Infection in the Organ Transplant Recipient. In: Rubin, R.H., Young, L.S., Van Furth, R. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/0-306-47527-8_17
Download citation
DOI: https://doi.org/10.1007/0-306-47527-8_17
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46693-9
Online ISBN: 978-0-306-47527-6
eBook Packages: Springer Book Archive